Alpha-Cypermethrin; Pesticide Tolerances, 7266-7275 [2013-02206]

Download as PDF 7266 Federal Register / Vol. 78, No. 22 / Friday, February 1, 2013 / Rules and Regulations 2004, the Coast Guard established regulations for the security of Department of Defense assets and military cargo in the navigable waters of Puget Sound to and adjacent waters. (See 69 FR 52600, Aug. 27, 2004). When subject to enforcement, this regulation prohibits persons and vessels from the immediate vicinity of these facilities during military cargo loading and unloading operations. The security zone will also provide for the regulation of vessel traffic in the vicinity of military cargo loading facilities in the navigable waters of the United States. In addition, the regulation establishes requirements for all vessels to obtain permission of the COTP or Designated Representative, including the Vessel Traffic Service (VTS), to enter, move within, or exit these security zones when they are enforced. Entry into this zone is prohibited unless otherwise exempted or excluded under 33 CFR 165.1321 or unless authorized by the Captain of the Port or Designated Representative. This notice is issued under authority of 33 CFR 165.1321 and 5 U.S.C. 552 (a). In addition to this notice in the Federal Register, the Coast Guard will provide the maritime community with notification of this enforcement period via marine information broadcasts and on-scene assets. If the COTP determines that the regulated area need not be enforced for the full duration stated in this notice, a Broadcast Notice to Mariners may be used to grant general permission to enter the regulated area. Dated: January 23, 2013. S.J. Ferguson, Captain, U.S. Coast Guard, Captain of the Port, Puget Sound. BILLING CODE 9110–04–P ENVIRONMENTAL PROTECTION AGENCY 40 CFR Part 180 [EPA–HQ–OPP–2010–0234; FRL–9376–1] Alpha-Cypermethrin; Pesticide Tolerances Environmental Protection Agency (EPA). ACTION: Final rule. srobinson on DSK4SPTVN1PROD with RULES AGENCY: This regulation establishes tolerances for residues of alphacypermethrin, in or on multiple commodities which are identified and discussed later in this document. BASF Corporation requested these tolerances under the Federal Food, Drug, and Cosmetic Act (FFDCA). VerDate Mar<15>2010 16:08 Jan 31, 2013 Jkt 229001 I. General Information A. Does this action apply to me? You may be potentially affected by this action if you are an agricultural producer, food manufacturer, or pesticide manufacturer. The following list of North American Industrial Classification System (NAICS) codes is not intended to be exhaustive, but rather provides a guide to help readers determine whether this document applies to them. Potentially affected entities may include: • Crop production (NAICS code 111). • Animal production (NAICS code 112). • Food manufacturing (NAICS code 311). • Pesticide manufacturing (NAICS code 32532). [FR Doc. 2013–02133 Filed 1–31–13; 8:45 am] SUMMARY: This regulation is effective February 1, 2013. Objections and requests for hearings must be received on or before April 2, 2013, and must be filed in accordance with the instructions provided in 40 CFR part 178 (see also Unit I.C. of the SUPPLEMENTARY INFORMATION). ADDRESSES: The docket for this action, identified by docket identification (ID) number EPA–HQ–OPP–2010–0234, is available at https://www.regulations.gov or at the Office of Pesticide Programs Regulatory Public Docket (OPP Docket) in the Environmental Protection Agency Docket Center (EPA/DC), EPA West Bldg., Rm. 3334, 1301 Constitution Ave. NW., Washington, DC 20460–0001. The Public Reading Room is open from 8:30 a.m. to 4:30 p.m., Monday through Friday, excluding legal holidays. The telephone number for the Public Reading Room is (202) 566–1744, and the telephone number for the OPP Docket is (703) 305–5805. Please review the visitor instructions and additional information about the docket available at https://www.epa.gov/dockets. FOR FURTHER INFORMATION CONTACT: BeWanda Alexander, Registration Division (7505P), Office of Pesticide Programs, Environmental Protection Agency, 1200 Pennsylvania Ave. NW., Washington, DC 20460–0001; telephone number: (703) 305–7460; email address: alexander.bewanda@epa.gov. SUPPLEMENTARY INFORMATION: DATES: B. How can I get electronic access to other related information? You may access a frequently updated electronic version of EPA’s tolerance regulations at 40 CFR part 180 through the Government Printing Office’s e-CFR site at https://ecfr.gpoaccess.gov/cgi/t/ text/text-idx?&c=ecfr&tpl=/ecfrbrowse/ Title40/40tab_02.tpl. PO 00000 Frm 00010 Fmt 4700 Sfmt 4700 C. How can I file an objection or hearing request? Under FFDCA section 408(g), 21 U.S.C. 346a, any person may file an objection to any aspect of this regulation and may also request a hearing on those objections. You must file your objection or request a hearing on this regulation in accordance with the instructions provided in 40 CFR part 178. To ensure proper receipt by EPA, you must identify docket ID number EPA–HQ– OPP–2010–0234 in the subject line on the first page of your submission. All objections and requests for a hearing must be in writing, and must be received by the Hearing Clerk on or before April 2, 2013. Addresses for mail and hand delivery of objections and hearing requests are provided in 40 CFR 178.25(b). In addition to filing an objection or hearing request with the Hearing Clerk as described in 40 CFR part 178, please submit a copy of the filing (excluding any Confidential Business Information (CBI)) for inclusion in the public docket. Information not marked confidential pursuant to 40 CFR part 2 may be disclosed publicly by EPA without prior notice. Submit the non-CBI copy of your objection or hearing request, identified by docket ID number EPA–HQ–OPP– 2010–0234, by one of the following methods: • Federal eRulemaking Portal: https:// www.regulations.gov. Follow the online instructions for submitting comments. Do not submit electronically any information you consider to be CBI or other information whose disclosure is restricted by statute. • Mail: OPP Docket, Environmental Protection Agency Docket Center (EPA/ DC), (28221T), 1200 Pennsylvania Ave. NW., Washington, DC 20460–0001. • Hand Delivery: To make special arrangements for hand delivery or delivery of boxed information, please follow the instructions at https:// www.epa.gov/dockets/contacts.htm. Additional instructions on commenting or visiting the docket, along with more information about dockets generally, is available at https://www.epa.gov/dockets. II. Summary of Petition-For Tolerance In the Federal Register of May 19, 2010 (75 FR 28009) (FRL–8823–2), EPA issued a document pursuant to FFDCA section 408(d)(3), 21 U.S.C. 346a(d)(3), announcing the filing of a pesticide petition (PP 0F7690) by BASF Corporation, 26 Davis Drive, P.O. Box 13528, Research Triangle Park, NC 27709–3528. The petition requested that 40 CFR 180.418 be amended by E:\FR\FM\01FER1.SGM 01FER1 Federal Register / Vol. 78, No. 22 / Friday, February 1, 2013 / Rules and Regulations srobinson on DSK4SPTVN1PROD with RULES establishing tolerances for residues of the insecticide alpha-cypermethrin in or on tree nuts, Group 14; dried shelled pea and bean, except soybean, subgroup 6C; corn, grain; pop corn; sweet corn; soybeans; and sugar beet, roots at 0.05 parts per million (ppm); succulent shelled pea and bean, subgroup 6B; and root and tuber vegetables, Group 1 at 0.1 ppm; cucurbit vegetables, Group 9; fruiting vegetables, Group 8; sugar beet, tops; and wheat, grain at 0.2 ppm; citrus fruit, Group 10 at 0.35 ppm; cottonseed; edible podded legume vegetable, subgroup 6A; and sorghum, grain at 0.5 ppm; and rice, grain at 1.5 ppm; citrus, dried pulp at 1.8 ppm; head and stem Brassica, subgroup 5A at 2.0 ppm; citrus, oil at 4.0 ppm; leafy vegetable, except Brassica, Group 4 at 10 ppm; and alfalfa, hay at 15 ppm. There were no comments received in response to the notice of filing. Based upon review of the data supporting the petition, EPA has established tolerances for alphacypermethrin ((R)-cyano(3phenoxyphenyl)methyl (1S,3S)-rel-3(2,2-dichloroethenyl)-2,2dimethylcyclopropane carboxylate) as explained in Unit IV.D. III. Aggregate Risk Assessment and Determination of Safety Section 408(b)(2)(A)(i) of FFDCA allows EPA to establish a tolerance (the legal limit for a pesticide chemical residue in or on a food) only if EPA determines that the tolerance is ‘‘safe.’’ Section 408(b)(2)(A)(ii) of FFDCA defines ‘‘safe’’ to mean that ‘‘there is a reasonable certainty that no harm will result from aggregate exposure to the pesticide chemical residue, including all anticipated dietary exposures and all other exposures for which there is reliable information.’’ This includes exposure through drinking water and in residential settings, but does not include occupational exposure. Section 408(b)(2)(C) of FFDCA requires EPA to give special consideration to exposure of infants and children to the pesticide chemical residue in establishing a tolerance and to ‘‘ensure that there is a reasonable certainty that no harm will result to infants and children from aggregate exposure to the pesticide chemical residue. * * *’’ Consistent with FFDCA section 408(b)(2)(D), and the factors specified in FFDCA section 408(b)(2)(D), EPA has reviewed the available scientific data and other relevant information in support of this action. EPA has sufficient data to assess the hazards of and to make a determination on aggregate exposure for alphacypermethrin including exposure VerDate Mar<15>2010 16:08 Jan 31, 2013 Jkt 229001 resulting from the tolerances established by this action. EPA’s assessment of exposures and risks associated with alpha-cypermethrin follows. A. Toxicological Profile EPA has evaluated the available toxicity data and considered its validity, completeness, and reliability as well as the relationship of the results of the studies to human risk. EPA has also considered available information concerning the variability of the sensitivities of major identifiable subgroups of consumers, including infants and children. Alpha-cypermethrin, cypermethrin, and zeta-cypermethrin are all pyrethroid insecticides and are isomer mixtures of the same chemical. The cypermethrins have been evaluated for a variety of toxic effects in experimental toxicity studies. Behavioral changes commonly seen with type II pyrethroids were consistently noted in the toxicology database for the cypermethrins. These behavioral changes included tremors, gait abnormalities, limb conditions, ataxia and hypersensitivity. Additionally, body weight changes were routinely observed and mortality was seen in a few studies in rats and dogs. Clinical signs were also noted in all acute neurotoxicity studies. Decreased activity, gait abnormalities, tremors, limb conditions, and hypersensitivity were observed at the mid and high doses. Additionally, slight nerve degeneration was seen in the acute neurotoxicity study with alphacypermethrin at the high dose. In the subchronic neurotoxicity studies with cypermethrin and zeta-cypermethrin, similar behavioral effects were seen along with decreased food consumption, body weight, and body weight gain. Acute toxicology studies conducted with cypermethrins indicate moderate acute toxicity via the oral route and low toxicity via the acute dermal or inhalation routes. Additionally, mild irritation was seen in primary eye and skin irritation studies but no dermal sensitization was observed. Dermal toxicity studies are available for zeta-cypermethrin (rat) and cypermethrin (rabbit), in which local irritation was observed in rats and rabbits at the highest doses tested. No systemic effects were observed in the 21-day dermal study in the rat conducted with zeta-cypermethrin at dose levels up to 1,000 milligrams/ kilogram/day (mg/kg/day). In the dermal toxicity study in rabbits with cypermethrin, systemic effects were observed (focal necrosis of the liver, decreased testicular weights, and decreased body weight in females). PO 00000 Frm 00011 Fmt 4700 Sfmt 4700 7267 However, these observations in the rabbit were not used for risk assessment because the testing method (i.e., abraded skin) does not simulate actual exposure and results in compromised test conditions. Additionally, there would be physiological differences between abraded and non-abraded animals, further undermining the relevance of these results for risk assessment. Developmental toxicity and reproduction studies are available for the cypermethrins. In the developmental toxicity studies in rats with cypermethrin and zetacypermethrin, there was no evidence of developmental toxicity up to the highest doses tested. Maternal toxicity included decreased body weight gain and food consumption in both chemicals. Splayed limbs, spasms and hypersensitivity to noise and convulsions were seen with cypermethrin, and ataxia, urine-stained abdominal fur, and fecal-stained fur were seen with zeta-cypermethrin. In the developmental toxicity study in rats with alpha-cypermethrin, offspring effects were limited to decreased fetal body weight. Maternal effects observations in the study were unsteady gait, piloerection, limb splay, and hypersensitivity to sound and touch at the same dose. In the developmental toxicity studies in rabbits with the cypermethrins, there was no evidence of developmental toxicity up to the highest dose tested. Maternal effects seen with cypermethrin included decreased body weight gain, anorexia, abdomino-genital staining, decreased feces, and red or pink material in the pan. With alphacypermethrin, maternal effects were body weight loss and decreased food consumption. Multi-generation reproduction studies in rats are available for cypermethrin and zetacypermethrin. In the reproduction study with cypermethrin, decreased body weight gain was observed in adult animals and decreased body weight gain was seen in offspring animals at the highest dose tested. In the reproduction study using zeta-cypermethrin, decreased body weight gain and mortality were observed in offspring animals in the presence of mortality, increased brain weights, decreased body weights, and neurotoxicity in maternal animals. No effects were observed in an immunotoxicity study in rats with alpha-cypermethrin up to the limit dose. Alpha-cypermethrin is classified as a Group C ‘‘Possible human carcinogen,’’ based on an increased incidence of lung adenomas and adenomas plus carcinomas combined in females in a mouse carcinogenicity study. The E:\FR\FM\01FER1.SGM 01FER1 7268 Federal Register / Vol. 78, No. 22 / Friday, February 1, 2013 / Rules and Regulations presence of common benign tumors (lung adenomas), in one species (mice) and one sex (female), with no increase in the proportion of malignant tumors or decrease in the time-to-tumor occurrence, together with the lack of mutagenic activity, was not considered strong enough to warrant a quantitative estimation of human risk. Quantification of risk using a non-linear approach (i.e., acute populationadjusted dose (aPAD), acute reference dose (aRfD)) adequately accounts for all chronic toxicity, including carcinogenicity that could result from exposure to alpha-cypermethrin. While the Agency would typically use a chronic population-adjusted dose (cPAD) to protect for cancer concerns, use of the aPAD is protective because increasing toxicity with increasing duration of exposure is not demonstrated for the cypermethrins. The no-observed-adverse-effect-level (NOAEL) observed in the mouse cancer study in which tumors were observed is 14 mg/kg/day, 2-fold higher than the point of departure (POD) used for acute risk assessment. The lowest-observedadverse-effect-level (LOAEL) in the mouse cancer study is 57 mg/kg/day based on liver effects, not tumor formation. The tumors were seen at 229 mg/kg/day. The acute POD of 7.16 mg/ kg/day selected for risk assessment is 32-fold lower than the dose that induced lung tumors in mice. Only the mouse study with cypermethrin resulted in tumor formation, no evidence of carcinogenicity was observed in cancer studies in rats with cypermethrin or mice with alphacypermethrin. Specific information on the studies received and the nature of the adverse effects caused by chemical name as well as the NOAEL and the LOAEL from the toxicity studies can be found at https:// www.regulations.gov in document Human Health Risk Assessment for New Active Ingredient—Alpha-cypermethrin at pg. 23 in docket ID number EPA–HQ– OPP–2012–0185–0005. B. Toxicological Points of Departure and Levels of Concern Once a pesticide’s toxicological profile is determined, EPA identifies toxicological POD and levels of concern (LOC) to use in evaluating the risk posed by human exposure to the pesticide. For hazards that have a threshold below which there is no appreciable risk, the toxicological POD is used as the basis for derivation of reference values for risk assessment. PODs are developed based on a careful analysis of the doses in each toxicological study to determine the dose at which no adverse effects are observed and the lowest dose at which adverse effects of concern are identified. Uncertainty/safety factors are used in conjunction with the POD to calculate a safe exposure level—generally referred to as a PAD or a reference dose (RfD)— and a safe margin of exposure (MOE). For non-threshold risks, EPA assumes that any amount of exposure will lead to some degree of risk. Thus, the Agency estimates risk in terms of the probability of an occurrence of the adverse effect expected in a lifetime. For more information on the general principles EPA uses in risk characterization and a complete description of the risk assessment process, see https:// www.epa.gov/pesticides/factsheets/ riskassess.htm. A summary of the toxicological endpoints for alpha-cypermethrin used for human risk assessment is shown in Table 1 of this unit. TABLE 1—SUMMARY OF TOXICOLOGICAL DOSES AND ENDPOINTS FOR ALPHA-CYPERMETHRIN FOR USE IN HUMAN HEALTH RISK ASSESSMENT Exposure/Scenario POD and uncertainty/safety factors RfD, PAD, LOC for risk assessment Acute dietary (children ≥6 years old and adults). Wolansky MDL1SD = 7.16 mg/kg/day. UFA = 10x UFH = 10x FQPA SF = 1x Wolansky BMDL1SD = 7.16 mg/kg/day. UFA = 10x UFH = 10x FQPA SF = 3x aRfD = 0.07 mg/kg/ day. aPAD = 0.07 mg/kg/ day. Wolansky BMD = 11.20 mg/kg/day based on motor activity. aRfD = 0.07 mg/kg/ day. aPAD = 0.023 mg/ kg/day. Wolansky BMD = 11.20 mg/kg/day based on motor activity. Acute dietary (children <6 years old). Study and toxicological effects Chronic dietary (All populations) Because of the rapid reversibility of the most sensitive neurotoxicity endpoint used for quantifying risks, there is no increase in hazard with increasing dosing duration, and therefore the acute dietary endpoint is protective for chronic exposure. Incidental oral short-term (1 to 30 days). Wolansky BMDL1SD = 7.16 mg/kg/day. UFA = 10x UFH = 10x FQPA SF = 3x Inhalation study ....... NOAEL = 0.01 mg/L HEC = 0.008 mg/L HED = 1.15 mg/kg/ day UFA = 3x UFH = 10x FQPA SF = 3x srobinson on DSK4SPTVN1PROD with RULES Inhalation short-term (1 to 30 days) (children <6 years old). VerDate Mar<15>2010 16:08 Jan 31, 2013 Jkt 229001 PO 00000 LOC for MOE = 300 Wolansky BMD = 11.20 mg/kg/day based on motor activity. Residential LOC for MOE = 100. 21-day inhalation study in the rat—LOAEL = .05 mg/L based on increased salivation. Frm 00012 Fmt 4700 Sfmt 4700 E:\FR\FM\01FER1.SGM 01FER1 Federal Register / Vol. 78, No. 22 / Friday, February 1, 2013 / Rules and Regulations 7269 TABLE 1—SUMMARY OF TOXICOLOGICAL DOSES AND ENDPOINTS FOR ALPHA-CYPERMETHRIN FOR USE IN HUMAN HEALTH RISK ASSESSMENT—Continued POD and uncertainty/safety factors RfD, PAD, LOC for risk assessment Study and toxicological effects Inhalation short-term (1 to 30 days) (children ≥6 years old and adults) (1 to 6 months). Inhalation study NOAEL = 0.01 mg/L. HEC = 0.008 mg/L HED = 1.15 mg//kg/ day UFA = 3x UFH = 10x FQPA SF = 1x LOC for MOE = 30 .. 21-day inhalation study in the rat—LOAEL = 0.05 mg/L based on increased salvation. Cancer (Oral, dermal, inhalation). Alpha cypermethrin has been classified as a Group C ‘‘Possible human carcinogen based on lung adenomas in female mice. Because of the rapid reversibility of the most sensitive neurotoxicity endpoint used for quantifying risks, there is no increase in hazard with increasing dosing duration. Therefore, the acute dietary endpoint is protective of the endpoints from repeat dosing studies, including cancer dietary exposures. Exposure/Scenario srobinson on DSK4SPTVN1PROD with RULES Point of Departure (POD) = A data point or an estimated point that is derived from observed dose-response data and used to mark the beginning of extrapolation to determine risk associated with lower environmentally relevant human exposures. NOAEL = no observed adverse effect level. LOAEL = lowest observed adverse effect level. BMD = benchmark dose. BMDL = benchmark dose (lower confidence limit). UF = uncertainty factor. UFA = extrapolation from animal to human (interspecies). UFH = potential variation in sensitivity among members of the human population (intraspecies). FQPA SF = FQPA Safety Factor. PAD = population adjusted dose (a = acute, c = chronic). RfD = reference dose. MOE = margin of exposure. LOC = level of concern. N/A = not applicable. HEC = human equivalent concentration. HED = human equivalent dose. Mg/kg/day = milligrams/kilogram/day. Mg/L = milligrams/liter. C. Exposure Assessment 1. Dietary exposure from food and feed uses. In evaluating dietary exposure to alpha-cypermethrin, EPA considered exposure under the petitioned-for tolerances as well as all existing cypermethrin and zetacypermethrin tolerances in 40 CFR 180.418. EPA assessed dietary exposures from alpha-cypermethrin in food as follows: i. Acute exposure. Quantitative acute dietary exposure and risk assessments are performed for a food-use pesticide, if a toxicological study has indicated the possibility of an effect of concern occurring as a result of a 1-day or single exposure. Such effects were identified for alpha-cypermethrin. In assessing aggregate risk to alphacypermethrin, EPA considered not only VerDate Mar<15>2010 16:08 Jan 31, 2013 Jkt 229001 the exposure associated with the proposed food uses for alphacypermethrin, but also the potential dietary and drinking water contribution and residential exposure from existing uses of cypermethrin and zetacypermethrin. In estimating acute dietary exposure, EPA used food consumption information from the U.S. Department of Agriculture (USDA) 1994–1996 and 1998 Nationwide Continuing Surveys of Food Intake by Individuals (CSFII). As to residue levels in food, EPA used a partially refined (probabilistic) dietary exposure assessment to determine the exposure and risk estimates which result from the use of cypermethrins on the crops listed under 40 CFR 180.418 and the proposed new uses. Anticipated residues from USDA Pesticide Data Program (PDP) monitoring data, field trial data, and empirical processing factors, and percent crop treated (PCT) estimates for some commodities were used where appropriate. ii. Chronic exposure. Based on the data summarized in Unit III.A., there is no increase in hazard from repeated exposures to alpha-cypermethrin; the acute dietary exposure assessment is higher than for chronic dietary exposures because the acute exposure levels are greater than the chronic exposure levels, therefore, a chronic dietary risk assessment was not conducted. iii. Cancer. As noted in Unit III.A., the Agency has determined that quantification of risk using a non-linear approach (i.e., aPAD) will adequately account for all chronic toxicity, including carcinogenicity, that could result from exposure to alphacypermethrin. Additionally, because an assessment of cancer risk would estimate exposure based on average PO 00000 Frm 00013 Fmt 4700 Sfmt 4700 residue levels and the acute assessment used high-end residue levels, the acute dietary assessment will be protective of any cancer effects resulting from consumption of alpha-cypermethrin residues in foods. iv. Anticipated residue and PCT information. Section 408(b)(2)(E) of FFDCA authorizes EPA to use available data and information on the anticipated residue levels of pesticide residues in food and the actual levels of pesticide residues that have been measured in food. If EPA relies on such information, EPA must require pursuant to FFDCA section 408(f)(1) that data be provided 5 years after the tolerance is established, modified, or left in effect, demonstrating that the levels in food are not above the levels anticipated. For the present action, EPA will issue such Data CallIns as are required by FFDCA section 408(b)(2)(E) and authorized under FFDCA section 408(f)(1). Data will be required to be submitted no later than 5 years from the date of issuance of these tolerances demonstrating that the levels in food are not above the levels anticipated. Section 408(b)(2)(F) of FFDCA states that the Agency may use data on the actual percent of food treated for assessing chronic dietary risk only if: • Condition a: The data used are reliable and provide a valid basis to show what percentage of the food derived from such crop is likely to contain the pesticide residue. • Condition b: The exposure estimate does not underestimate exposure for any significant subpopulation group. • Condition c: Data are available on pesticide use and food consumption in a particular area, the exposure estimate does not understate exposure for the population in such area. E:\FR\FM\01FER1.SGM 01FER1 srobinson on DSK4SPTVN1PROD with RULES 7270 Federal Register / Vol. 78, No. 22 / Friday, February 1, 2013 / Rules and Regulations In addition, the Agency must provide for periodic evaluation of any estimates used. To provide for the periodic evaluation of the estimate of PCT as required by FFDCA section 408(b)(2)(F), EPA may require registrants to submit data on PCT. The following maximum PCT estimates were used in the acute dietary risk assessment, which was relied on in assessing chronic risk, for the following crops that are currently registered for the cypermethrins: Almonds, 2.5%; apples, 2.5%; broccoli, 30%; cabbage, 30%; carrot, 10%; cauliflower, 25%; celery, 60%; cherries, 5%; grapefruit, 50%; green beans, 20%; green peas, 15%; lemon, 2.5%; lettuce, 65%; orange, 45%; peach, 5%; peppers, 30%; potato, 5%; sweet corn, 20%; spinach, 45%; tomato, 10%; and watermelon, 10%. The following average PCT estimates were used to calculate average dietary exposures in order to assess short-term aggregate risk to the cypermethrins: Almonds, 1%; apples, 1%; broccoli, 20%; cabbage, 15%; carrot, 2.5%; cauliflower, 15%; celery, 35%; cherries, 5%; grapefruit, 35%; green beans, 15%; green peas, 10%; lemon, 1%; lettuce, 55%; orange, 35%; peach, 2.5%; peppers, 15%; potato, 1%; sweet corn, 15%; spinach, 30%; tomato, 5%; and watermelon, 2.5%. The zetacypermethrin PCT data was used as a surrogate for future PCT of alphacypermethrin. In most cases, EPA uses available data from the U.S. Department of Agriculture/National Agricultural Statistics Service (USDA/NASS), proprietary market surveys, and the National Pesticide Use Database for the chemical/crop combination for the most recent 6–7 years. EPA uses an average PCT for chronic dietary risk analysis. The average PCT figure for each existing use is derived by combining available public and private market survey data for that use, averaging across all observations, and rounding to the nearest 5%, except for those situations in which the average PCT is less than 1. In those cases, 1% is used as the average PCT and 2.5% is used as the maximum PCT. EPA uses a maximum PCT for acute dietary risk analysis. The maximum PCT figure is the highest observed maximum value reported within the recent 6 years of available public and private market survey data for the existing use and rounded up to the nearest multiple of 5%. The Agency believes that the three conditions discussed in Unit III.C.1.iv. have been met. With respect to Condition a, PCT estimates are derived from Federal and private market survey data, which are reliable and have a valid VerDate Mar<15>2010 16:08 Jan 31, 2013 Jkt 229001 basis. The Agency is reasonably certain that the percentage of the food treated is not likely to be an underestimation. As to Conditions b and c, regional consumption information and consumption information for significant subpopulations is taken into account through EPA’s computer-based model for evaluating the exposure of significant subpopulations including several regional groups. Use of this consumption information in EPA’s risk assessment process ensures that EPA’s exposure estimate does not understate exposure for any significant subpopulation group and allows the Agency to be reasonably certain that no regional population is exposed to residue levels higher than those estimated by the Agency. Other than the data available through national food consumption surveys, EPA does not have available reliable information on the regional consumption of food to which alpha-cypermethrin may be applied in a particular area. 2. Dietary exposure from drinking water. The Agency used screening level water exposure models in the dietary exposure analysis and risk assessment for alpha-cypermethrin in drinking water. These simulation models take into account data on the physical, chemical, and fate/transport characteristics of alpha-cypermethrin. Further information regarding EPA drinking water models used in pesticide exposure assessment can be found at https://www.epa.gov/oppefed1/models/ water/index.htm. Based on the First Index Reservoir Screening Tool (FIRST) and Screening Concentration in Ground Water (SCI– GROW) models the estimated drinking water concentrations (EDWCs) of alphacypermethrin were 3.77 parts per billion (ppb) for surface water and 0.0036 ppb for ground water. In the dietary risk assessment conducted to support the proposed uses, EPA incorporated the surface water EDWCs directly into the dietary model, since surface water estimates were higher than those provided for ground water. 3. From non-dietary exposure. The term ‘‘residential exposure’’ is used in this document to refer to nonoccupational, non-dietary exposure (e.g., for lawn and garden pest control, indoor pest control, termiticides, and flea and tick control on pets). Alphacypermethrin is not registered for any specific use patterns that would result in residential exposure. There are no proposed residential uses associated with alpha-cypermethrin; however, there are registered residential uses for cypermethrin and zeta-cypermethrin that have been reassessed to reflect PO 00000 Frm 00014 Fmt 4700 Sfmt 4700 updates to the Agency’s 2012 Residential standard operating procedures (SOPs) along with policy changes for body weight assumptions and inhalation rates. These revised residential exposures have been incorporated into the human health aggregate risk assessment for alphacypermethrin, which must consider all potential exposures to the cypermethrins. The Agency has determined that short-term exposures are likely to occur in a residential setting for the cypermethrins; however, they do not increase in potency with repeated dosing. EPA assessed residential exposure using the following assumptions. The quantitative exposure/risk assessment developed for residential handlers is based on the following scenarios: • Mixer/loader/applicator using hoseend sprayer on turf; • Mixer/loader/applicator using backpack on turf and gardens; • Mixer/loader/applicator using manually pressurized handwand for indoor surfaces; • Application via aerosol can for indoor surfaces and space. Since a dermal endpoint was not identified, only a quantitative inhalation handler exposure assessment was performed. Residential handler inhalation exposure estimates were calculated based on a human equivalent concentration and human equivalent dose which reflect 24 hours of exposure. Since handler exposure is expected to be significantly less than 24 hours, the inhalation exposure estimates are sufficiently protective of all scenarios (turf, gardens, and indoor surface space). Although there is potential inhalation exposure resulting from the application of dog tags and spot-on products for pets, inhalation exposure is considered negligible for these scenarios and therefore a quantitative assessment was not performed for these uses. There is the potential for postapplication exposure for individuals as a result of being in an environment that has been previously treated with cypermethrin or zeta-cypermethrin. However, the combination of low vapor pressure for chemicals typically used as active ingredients in outdoor residential pesticide products and dilution in outdoor air is likely to result in minimal inhalation exposure. Therefore, a quantitative post-application inhalation exposure assessment for cypermethrin turf uses was not conducted. Since a dermal endpoint was not identified, and indoor post-application inhalation exposure resulting from aerosol space sprays, foggers, and pet (i.e., dog tag, spot-on) uses is negligible, the only E:\FR\FM\01FER1.SGM 01FER1 srobinson on DSK4SPTVN1PROD with RULES Federal Register / Vol. 78, No. 22 / Friday, February 1, 2013 / Rules and Regulations potential post-application exposure pathways of concern are incidental oral for children, and post-application inhalation exposure for adults and children resulting from indoor crack and crevice applications made with a manually pressurized handwand. The quantitative exposure/risk assessment for residential post-application exposures is based on the following scenarios: • Incidental oral (hand-to-mouth, object-to-mouth, and soil ingestion) exposure from turf for children. • Incidental oral (hand-to-mouth and object-to-mouth) exposure from indoor foggers for children. • Incidental oral (hand-to-mouth and object-to-mouth) exposure from pets for children. • Inhalation exposure for adults and children resulting from crack and crevice application to an indoor surface. • Incidental oral (hand-to-mouth and object-to-mouth) exposure for children from indoor surface applications. Risk estimates resulting from different exposure routes may be combined when it is likely that they can occur simultaneously based on the use pattern and when the toxicological effects across different routes of exposure are the same. Although, in the case of children, inhalation and incidental oral exposure routes share a common toxicological endpoint, risk estimates were not combined for those routes for turf, indoor fogger, and pet since postapplication inhalation exposure is considered negligible. However, inhalation and incidental oral exposures were combined for post-application risk assessment associated with the indoor crack and crevice use. Inhalation and incidental oral routes have different LOCs. Therefore, in order to combine exposure from the various routes, the aggregate risk index (ARI) approach is used to estimate exposure and risk. When this approach is used, aggregate risks are not of concern provided the calculated ARI is greater than 1. The incidental oral scenarios from indoor exposure following crack and crevice applications and outdoor exposure from turf were not combined, not only because they are not likely to co-occur, but also because combining these scenarios would be overlyconservative due to the conservative nature of each of the individual assessments. Further information regarding EPA standard assumptions and generic inputs for residential exposures may be found at https://www.epa.gov/pesticides/ trac/science/trac6a05.pdf. 4. Cumulative effects from substances with a common mechanism of toxicity. VerDate Mar<15>2010 16:08 Jan 31, 2013 Jkt 229001 Section 408(b)(2)(D)(v) of FFDCA requires that, when considering whether to establish, modify, or revoke a tolerance, the Agency consider ‘‘available information’’ concerning the cumulative effects of a particular pesticide’s residues and ‘‘other substances that have a common mechanism of toxicity.’’ The Agency is required to consider the cumulative risks of chemicals sharing a common mechanism of toxicity. The Agency has determined that the pyrethroids and pyrethrins, including the cypermethrins, share a common mechanism of toxicity. The members of this group share the ability to interact with voltage-gated sodium channels, ultimately leading to neurotoxicity. The cumulative risk assessment for the pyrethroids and pyrethrins was published in the Federal Register on November 9, 2011 (76 FR 69726) (FRL–8888–9), and is available at https://www.regulations.gov in the public docket, EPA–HQ–OPP–2011–0746. Further information about the determination that pyrethroids and pyrethrins share a common mechanism of toxicity may be found in document ID: EPA–HQ–OPP–2008–0489–0006. The cypermethrins were included in a recent cumulative risk assessment for pyrethrins and pyrethroids. The proposed new uses of alphacypermethrin will not significantly impact the cumulative assessment because, in the cumulative assessment, residential exposure was the greatest contributor to the total exposure. There are no new residential uses for the cypermethrins, and the proposed new uses will have no impact on the residential component of the cumulative risk estimates. Dietary exposures make a minor contribution to total pyrethroid exposure. The dietary exposure assessment performed in support of the pyrethroid cumulative was much more highly refined than that performed for the single chemical. The dietary exposure assessment for the single chemical included conservative assumptions, using field trial data for many commodities, including the proposed new uses, with the assumption of 100 PCT, and the most sensitive apical endpoint in the cypermethrins hazard database was selected to derive the POD. Additionally, the POD selected for alpha-cypermethrin is specific to the cypermethrins, whereas the POD selected for the cumulative assessment was based on-common-mechanism-ofaction data that are appropriate for all 20 pyrethroids included in the cumulative assessment. PO 00000 Frm 00015 Fmt 4700 Sfmt 4700 7271 For information regarding EPA’s efforts to evaluate the risk of exposure to pyrethroids, refer to https:// www.epa.gov/oppsrrd1/reevaluation/ pyrethroids-pyrethrins.html. D. Safety Factor for Infants and Children 1. In general. Section 408(b)(2)(C) of FFDCA provides that EPA shall apply an additional tenfold (10X) margin of safety for infants and children in the case of threshold effects to account for prenatal and postnatal toxicity and the completeness of the database on toxicity and exposure unless EPA determines based on reliable data that a different margin of safety will be safe for infants and children. This additional margin of safety is commonly referred to as the Food Quality Protection Act (FQPA) Safety Factor (SF). In applying this provision, EPA either retains the default value of 10X, or uses a different additional safety factor when reliable data available to EPA support the choice of a different factor. 2. Prenatal and postnatal sensitivity. In guideline developmental and reproduction studies with the cypermethrins, there was no evidence of increased qualitative or quantitative susceptibility in rats or rabbits. In a guideline developmental neurotoxicity (DNT) study with zetacypermethrin, there was increased sensitivity in the offspring based on body weight changes in pups (5%–10%) in the absence of treatment-related effects in maternal animals. Although, there was a 5%–8% decrease in maternal body weight in this study, a body weight decrease of <10% is generally not considered adverse in adults, as this is considered to be within the range of variability because the magnitude of body weight per se is typically small (as an example, a 3 gram (g) decrease in body weight from a 338 g rat), and adults are no longer in the growth/development phase. In contrast, the offspring are at a stage of growth and development and are therefore expected to be gaining rather than losing weight. Thus, a smaller percent decrease in body weight is considered adverse in the young relative to adults. In the case of zeta-cypermethrin, the decrease in body weight of the young is comparable to adults; however, it was considered adverse in the young but not in the adults. This disparity in interpretation leads to an apparent increase in sensitivity in the young; however, concern is reduced since the magnitude of body weight decrements was similar in adult and young animals. The results from the DNT study are very similar to results observed in the reproduction E:\FR\FM\01FER1.SGM 01FER1 srobinson on DSK4SPTVN1PROD with RULES 7272 Federal Register / Vol. 78, No. 22 / Friday, February 1, 2013 / Rules and Regulations studies where body weight (bwt) changes (decreased body weight gain) were seen in maternal and offspring animals at doses similar to those in the DNT study, with no indication of increased susceptibility. Therefore, there is no residual concern for effects observed in the study. Additionally, there are well-characterized dose responses, with clear NOAELs and LOAELs for effects seen in the DNT and reproduction studies, and the endpoints and PODs selected for risk assessment are protective. High-dose LD50 studies (studies assessing what dose results in lethality to 50% of the tested population) in the scientific literature indicate that pyrethroids can result in increased quantitative sensitivity in the young, typically in the form of neurotoxicity. Examination of pharmacokinetic and pharmacodynamic data indicates that the sensitivity observed at high doses is related to pyrethroid age-dependent pharmacokinetics—the activity of enzymes associated with the metabolism of pyrethroids. With otherwise equivalent administered doses for adults and juveniles, predictive pharmacokinetic models indicate that the differential adultjuvenile pharmacokinetics will result in a 3X greater dose at the target organ in juveniles compared to adults. No evidence of increased quantitative or qualitative susceptibility was seen in the pyrethroid scientific literature related to pharmacodynamics (the effect of pyrethroids at the target tissue) both with regard to inter-species differences between rats and humans and to differences between juveniles and adults. Specifically, there are in vitro pharmacodynamic data and in vivo data indicating similar responses between adult and juvenile rats at low doses and data indicating that the rat is a conservative model compared to the human based on species-specific pharmacodynamics of homologous sodium channel isoforms in rats and humans. 3. Conclusion. The FQPA SF was reduced to 1X for the general population, women of child bearing age and children > 6 years. For exposures from birth to <6 years of age, a 3X FQPA SF was retained based on the following considerations: i. The toxicology database for the cypermethrins is not complete. While the database is considered to be complete with respect to the guideline toxicity studies for alpha-cypermethrin, EPA lacks additional data to fully characterize the potential for juvenile sensitivity to neurotoxic effects of pyrethroids. In light of the literature VerDate Mar<15>2010 16:08 Jan 31, 2013 Jkt 229001 studies indicating a possibility of increased sensitivity to cypermethrins in juvenile rats at high doses, EPA has requested proposals for study protocols which could identify and quantify potential juvenile sensitivity. However, when evaluated together, the toxicity studies for the cypermethrins can be used to characterize toxic effects including potential developmental and reproductive toxicity, immunotoxicity, and neurotoxicity. Acceptable developmental toxicity studies in rats and rabbits, reproduction studies in rats, neurotoxicity studies (acute neurotoxicity (ACN), subchronic neurotoxicity (SCN), and DNT) in rats, and immunotoxicity studies in rats are available. In addition, route-specific dermal and inhalation studies are available. ii. After reviewing the extensive body of data and peer-reviewed literature on pyrethroids, the Agency has reached a number of conclusions regarding fetal juvenile sensitivity for pyrethroids, including the following: • Based on an evaluation of over 70 guideline toxicity studies for 24 pyrethroids submitted to the Agency, including prenatal developmental toxicity studies in rats and rabbits, and prenatal and postnatal multi-generation reproduction toxicity studies and DNTs in rats in support of pyrethroid registrations, there is no evidence that pyrethroids directly impact developing fetuses. None of the studies show any indications of fetal toxicity at doses that do not cause maternal toxicity. • Increased susceptibility was seen in offspring animals in the DNT study with zeta-cypermethrin (decreased pup body weights) and DNT and reproduction studies with beta-cyfluthrin (decreased body weights and tremors). However, the reductions in body weight and the other non-specific effects occur at higher doses than neurotoxicity, the effect of concern for pyrethroids. The available developmental and reproduction guideline studies in rats with zeta-cypermethrin did not show increased sensitivity in the young to neurotoxic effects. Overall, findings of increased sensitivity in juvenile animals in pyrethroid studies are rare. Therefore, the residual concern for the postnatal effects is reduced. • High-dose LD50 studies (studies assessing what dose results in lethality to 50% of the tested population) in the scientific literature indicate that pyrethroids can result in increased quantitative sensitivity to juvenile animals. Examination of pharmacokinetic and pharmacodynamic data indicates that the sensitivity observed at high doses is related to PO 00000 Frm 00016 Fmt 4700 Sfmt 4700 pyrethroid age-dependent pharmacokinetics—the activity of enzymes associated with the metabolism of pyrethroids. Furthermore, a rat PBPK model predicts a three-fold increase of pyrethroid concentration in juvenile brain compared to adults at high doses. • In vitro pharmacodynamic data and in vivo data indicate that adult and juvenile rats have similar responses to pyrethroids at low doses and therefore juvenile sensitivity is not expected at relevant environmental exposures. Further, data also show that the rat is a conservative model compared to the human based on species-specific pharmacodynamics of homologous sodium channel isoforms. iii. There are no residual uncertainties with regard to dietary and residential exposure. The dietary exposure assessments are based on high-end health protective residue levels (that account for parent and metabolites of concern), processing factors, and PCT assumptions. Furthermore, conservative, upper-bound assumptions were used to determine exposure through drinking water and residential sources, such that these exposures have not been underestimated. Taking all of this information into account, EPA has reduced the FQPA SF for women of child-bearing age and children over 6 years to 1X since after evaluation of over 70 guideline toxicity studies submitted to the Agency, including prenatal developmental toxicity studies in rats and rabbits, and multi-generation reproduction toxicity studies and DNTs in rats, there is no evidence that pyrethroids directly impact developing fetuses. Additionally, none of the studies show any indications of fetal/offspring toxicity at doses that do not cause maternal toxicity. However, since there remains some uncertainty as to juvenile sensitivity due to the findings in the high-dose LD50 studies, EPA is retaining a FQPA SF for infants and children less than 6 years of age. This age group is a close approximation to the most sensitive human population, children from birth to <6 years old. EPA is seeking additional data to further characterize the potential neurotoxic risk pyrethroid toxicity. However, EPA has reliable data that show that reducing the FQPA SF to 3X will protect the safety of infants and children. These data include: (a) data from guideline studies with zeta-cypermethrin at relatively high doses that show no sensitivity with regard to neurotoxic effects (the most sensitive effect for the pyrethroids) and no residual concern regarding overall E:\FR\FM\01FER1.SGM 01FER1 srobinson on DSK4SPTVN1PROD with RULES Federal Register / Vol. 78, No. 22 / Friday, February 1, 2013 / Rules and Regulations juvenile sensitivity (i.e., sensitivity seen in body weight changes occurred at doses above the level chosen for the POD); (b) data showing that the potential sensitivity at high doses is due to pharmacokinetics alone; (c) a rat PBPK model predicting a three-fold increase of pyrethroid concentration in juvenile brain compared to adults at high doses due to age-dependent pharmacokinetics; and (d) data indicating that the rat is a conservative model compared to the human based on species-specific pharmacodynamics of homologous sodium channel isoforms. For several reasons, EPA concludes these data show that a 3X factor is protective of the safety of infants and children. First, it is likely that the extensive guideline studies with zetacypermethrin showing no neurotoxicity sensitivity between adults and juveniles better characterize the potential sensitivity of juvenile animals than the LD50 studies. The high doses that produced juvenile sensitivity in the literature studies are well above normal dietary or residential exposure levels of pyrethroids to juveniles and lower levels of exposure anticipated from dietary and residential uses are not expected to overwhelm the juvenile’s ability to metabolize pyrethroids, as occurred with the high doses used in the literature studies. The lack of increased neurotoxic sensitivity of the young in the overwhelming majority (69 of 70) of the prenatal and postnatal guideline studies for pyrethroids supports this conclusion, despite the relatively high doses used in those studies. Second, limited in vitro and in vivo data indicate similar pharmacodynamic response to pyrethroids between juvenile and adult rats. The portion of the uncertainty factor that accounts for potential pharmacodynamic differences between animals and humans (i.e., the interspecies extrapolation factor) is likely to overstate the risk of the cypermethrins given the data showing similarities in pharmacodynamics between animals and humans. For the inter-species factor, the pharmacodynamic portion of the factor is generally considered to be 3X. However, for pyrethroids the actual difference is likely to be lower than 3X. In addition, there are data that show that there are no lifestage pharmacodynamic differences between young and adult rats. Standard uncertainty factors, such as those used in the cypermethrin risk assessment, assume that there will be such differences. Finally, as indicated, pharmacokinetic modeling only predicts VerDate Mar<15>2010 16:08 Jan 31, 2013 Jkt 229001 a 3X difference between juveniles and adults. Thus, even if there is increased juvenile neurotoxic sensitivity and even if the existing interspecies and intraspecies factors do not provide extra protection due to the conservative nature of their pharmacodynamic components for pyrethroids, the 3X additional factor will protect the young. Therefore, the FQPA factor of 3X is protective of potential juvenile sensitivity. E. Aggregate Risks and Determination of Safety EPA determines whether acute and chronic dietary pesticide exposures are safe by comparing aggregate exposure estimates to the aPAD and cPAD. For linear cancer risks, EPA calculates the lifetime probability of acquiring cancer given the estimated aggregate exposure. Short-, intermediate-, and chronic-term risks are evaluated by comparing the estimated aggregate food, water, and residential exposure to the appropriate PODs to ensure that an adequate MOE exists. 1. Acute risk. Using the exposure assumptions discussed in this unit for acute exposure, the acute dietary exposure from food and water to alphacypermethrin will occupy 87% of the aPAD for all infants (<1 year old) and children 1–2 years old, the population groups receiving the greatest exposure. This assessment is considered to be conservative, because tolerance level residues and distributions of field trial data (as opposed to monitoring data) were used for many commodities. Additionally, although upper-bound estimates were used for drinking water, drinking water is not considered to be a major source of dietary exposure for the cypermethrins. 2. Chronic risk. Separate chronic and cancer dietary risk assessments were not conducted for the cypermethrins. Because of the rapid reversibility of the most sensitive neurotoxicity endpoint used for quantifying risks, there is no increase in hazard with increasing dosing duration, and therefore the acute dietary endpoint is protective for chronic and cancer dietary exposures. 3. Short-term risk. Short-term aggregate exposure takes into account short-term residential exposure plus chronic exposure to food and water (considered to be a background exposure level). Cypermethrin and zeta-cypermethrin are currently registered for uses that could result in short-term residential exposure, and the Agency has determined that it is appropriate to aggregate chronic exposure through food and water with short-term residential PO 00000 Frm 00017 Fmt 4700 Sfmt 4700 7273 exposures to the cypermethrins including alpha-cypermethrin. For assessing short-term aggregate risk, the average dietary exposure estimate was used since it represents a background exposure level from food and drinking water that may co-occur with residential exposures. Dietary and oral (hand to mouth) risks for children, and dietary and inhalation risks for adults were combined in this assessment, since the toxicological endpoints were the same. However, the level of concern (LOC) values were different (oral adults and children ≥6 years old = 100; children <6 years old = 300), while inhalation LOC = 30. Therefore, the respective risk estimates are combined using the aggregate risk index (ARI) approach. When this approach is used, aggregate risks are not of concern provided the calculated ARI is greater than 1. The ARI for adults was calculated to be 56 and the ARI for children was 2.3. Because these ARIs are greater than 1, the risk estimates are not of concern. 4. Intermediate-term risk. Intermediate-term aggregate exposure takes into account intermediate-term residential exposure plus chronic exposure to food and water (considered to be a background exposure level). An intermediate-term aggregate risk assessment was not conducted because the cypermethrins are acutely toxic and do not increase in potency with repeated dosing. Because the neurotoxicity POD used for acute risk assessment is lower (more protective) than PODs for longer durations of exposure and acute and short-term exposure levels are higher than longer term exposure levels, the acute and short-term aggregate assessments are protective for intermediate-term aggregate risks anticipated from the cypermethrins. 5. Aggregate cancer risk for U.S. population. For the reasons discussed in Unit III.A. (cancer effects are non-linear and appear at higher doses than acute effects) and Unit III.E.2. (chronic exposures are lower than acute exposures), the acute aggregate assessment is protective of potential cancer risk. 6. Determination of safety. Based on these risk assessments, EPA concludes that there is a reasonable certainty that no harm will result to the general population, or to infants and children from aggregate exposure to the cypermethrin residues. E:\FR\FM\01FER1.SGM 01FER1 7274 Federal Register / Vol. 78, No. 22 / Friday, February 1, 2013 / Rules and Regulations IV. Other Considerations srobinson on DSK4SPTVN1PROD with RULES A. Analytical Enforcement Methodology Adequate tolerance-enforcement methods are available in PAM Volume II for determining residues of cypermethrin, zeta-cypermethrin and alpha-cypermethrin in plant (Method I) and livestock (Method II) commodities. Both methods are gas chromatographic methods with electron-capture detection (GC/ECD), and have undergone successful Agency petition method validations (PMVs). Method I has a limit of detection (LOD) of 0.01 ppm, and Method II has LODs of 0.005 ppm in milk, and 0.01 ppm in livestock tissues. These methods are not stereospecific; thus no distinction is made between residues of cypermethrin (all eight stereoisomers), zeta-cypermethrin (enriched in four isomers) and alphacypermethrin (two isomers). B. International Residue Limits In making its tolerance decisions, EPA seeks to harmonize U.S. tolerances with international standards whenever possible, consistent with U.S. food safety standards and agricultural practices. EPA considers the international maximum residue limits (MRLs) established by the Codex Alimentarius Commission (Codex), as required by FFDCA section 408(b)(4). The Codex Alimentarius is a joint United Nations Food and Agriculture Organization/World Health Organization food standards program, and it is recognized as an international food safety standards-setting organization in trade agreements to which the United States is a party. EPA may establish a tolerance that is different from a Codex MRL; however, FFDCA section 408(b)(4) requires that EPA explain the reasons for departing from the Codex level. There are multiple Codex MRLs for alpha-cypermethrin, but all are in conjunction with MRLs for total cypermethrin isomers (no MRLs have been established solely for alphacypermethrin). However, although the definitions of the isomers covered differ formally between U.S. tolerances and Codex MRLs, the definitions of coverage are effectively harmonized since the tolerance enforcement methods are not stereospecific, and thus do not distinguish between residues of cypermethrin, zeta-cypermethrin and alpha-cypermethrin. For enforcement purposes, the same moiety is being regulated. As to harmonization of tolerance levels, U.S. tolerances and Codex MRLs are identical for tree nuts, tomatoes, and cattle meat byproducts. However, the proposed U.S. use VerDate Mar<15>2010 16:08 Jan 31, 2013 Jkt 229001 patterns for all of the other crops for which U.S. tolerances are being established differ from the use patterns underlying the Codex MRLs associated with these crops. Therefore, these U.S. tolerances cannot be established at the same level as the Codex MRLs. C. Response to Comments There were no comments received on this petition. D. Revisions to Petitioned-For Tolerances No revisions to the tolerance levels in the petition, as proposed by BASF, were necessary. However, all the proposed commodity definitions (except for soybean, seed) were revised to reflect the correct commodity definitions, per the Agency’s current commodity vocabulary. Additionally, appropriate tolerances for alpha-cypermethrin in livestock commodities (which were not proposed by BASF) were added (reflecting those established for zetacypermethrin), based on the potential for residues in livestock feed items associated with the proposed uses. V. Conclusion Therefore, tolerances are established for residues of alpha-cypermethrin ((R)cyano(3-phenoxyphenyl)methyl (1S,3S)rel-3-(2,2-dichloroethenyl)-2,2dimethylcyclopropane carboxylate, in or on cotton, undelinted seed, vegetable, legume, edible podded, subgroup 6A, and sorghum, grain, grain at 0.50 ppm; vegetable, root and tuber, group 1, except sugar beet, pea and bean, succulent shelled, subgroup 6B, and hog, fat at 0.10 ppm; nut, tree, group 14– 12, pea and bean, dried shelled, except soybean, subgroup 6C, corn, field, grain, corn, pop, grain, corn, sweet, kernel plus cob with husks removed, soybean, seed, beet, sugar, roots, cattle, meat byproducts, egg, goat, meat byproducts, hog, meat, horse, meat byproducts, poultry, fat, poultry, meat, and sheep, meat byproducts at 0.05 ppm; vegetable, leafy, group 4 at 10 ppm; Brassica, head and stem, subgroup 5A at 2.0 ppm; rice, grain at 1.5 ppm; vegetable, cucurbit, group 9, vegetable, fruiting, group 8–10, beet, sugar, tops, wheat, grain, cattle, meat, goat, meat, horse, meat, and sheep, meat at 0.20 ppm; fruit, citrus, group 10–10 at 0.35 ppm; citrus, oil at 4.0 ppm; citrus, dried pulp at 1.8 ppm; alfalfa, hay at 15 ppm; cattle, fat, goat, fat, horse, fat, sheep, fat at 1.0 ppm; and milk, fat, reflecting at 0.10 ppm in whole milk at 2.5 ppm. PO 00000 Frm 00018 Fmt 4700 Sfmt 4700 VI. Statutory and Executive Order Reviews This final rule establishes tolerances under FFDCA section 408(d) in response to a petition submitted to the Agency. The Office of Management and Budget (OMB) has exempted these types of actions from review under Executive Order 12866, entitled ‘‘Regulatory Planning and Review’’ (58 FR 51735, October 4, 1993). Because this final rule has been exempted from review under Executive Order 12866, this final rule is not subject to Executive Order 13211, entitled ‘‘Actions Concerning Regulations That Significantly Affect Energy Supply, Distribution, or Use’’ (66 FR 28355, May 22, 2001) or Executive Order 13045, entitled ‘‘Protection of Children from Environmental Health Risks and Safety Risks’’ (62 FR 19885, April 23, 1997). This final rule does not contain any information collections subject to OMB approval under the Paperwork Reduction Act (PRA) (44 U.S.C. 3501 et seq.), nor does it require any special considerations under Executive Order 12898, entitled ‘‘Federal Actions to Address Environmental Justice in Minority Populations and Low-Income Populations’’ (59 FR 7629, February 16, 1994). Since tolerances and exemptions that are established on the basis of a petition under FFDCA section 408(d), such as the tolerance in this final rule, do not require the issuance of a proposed rule, the requirements of the Regulatory Flexibility Act (RFA) (5 U.S.C. 601 et seq.), do not apply. This final rule directly regulates growers, food processors, food handlers, and food retailers, not States or tribes, nor does this action alter the relationships or distribution of power and responsibilities established by Congress in the preemption provisions of FFDCA section 408(n)(4). As such, the Agency has determined that this action will not have a substantial direct effect on States or tribal governments, on the relationship between the national government and the States or tribal governments, or on the distribution of power and responsibilities among the various levels of government or between the Federal Government and Indian tribes. Thus, the Agency has determined that Executive Order 13132, entitled ‘‘Federalism’’ (64 FR 43255, August 10, 1999) and Executive Order 13175, entitled ‘‘Consultation and Coordination with Indian Tribal Governments’’ (65 FR 67249, November 9, 2000) do not apply to this final rule. In addition, this final rule does not impose any enforceable duty or contain any unfunded mandate E:\FR\FM\01FER1.SGM 01FER1 Federal Register / Vol. 78, No. 22 / Friday, February 1, 2013 / Rules and Regulations as described under Title II of the Unfunded Mandates Reform Act of 1995 (UMRA) (2 U.S.C. 1501 et seq.). This action does not involve any technical standards that would require Agency consideration of voluntary consensus standards pursuant to section 12(d) of the National Technology Transfer and Advancement Act of 1995 (NTTAA) (15 U.S.C. 272 note). VII. Congressional Review Act Pursuant to the Congressional Review Act (5 U.S.C. 801 et seq.), EPA will submit a report containing this rule and other required information to the U.S. Senate, the U.S. House of Representatives, and the Comptroller General of the United States prior to publication of the rule in the Federal Register. This action is not a ‘‘major rule’’ as defined by 5 U.S.C. 804(2). List of Subjects in 40 CFR Part 180 Environmental protection, Administrative practice and procedure, Agricultural commodities, Pesticides and pests, Reporting and recordkeeping requirements. Dated: January 23, 2013. Steven Bradbury, Director, Office of Pesticide Programs. Therefore, 40 CFR chapter I is amended as follows: PART 180—[AMENDED] 1. The authority citation for part 180 continues to read as follows: ■ Authority: 21 U.S.C. 321(q), 346a and 371. 2. In § 180.418 add paragraph (a)(3) to read as follows: ■ srobinson on DSK4SPTVN1PROD with RULES § 180.418 Cypermethrin and an isomer alpha-cypermethrin; tolerances for residues. Parts per million Commodity Alfalfa, hay .................................. Beet, sugar, roots ....................... VerDate Mar<15>2010 16:08 Jan 31, 2013 15 0.05 Jkt 229001 Beet, sugar, tops ........................ Brassica, head and stem, subgroup 5A ................................. Cattle, fat .................................... Cattle, meat ................................ Cattle, meat byproducts ............. Citrus, dried pulp ........................ Citrus, oil ..................................... Corn, field, grain ......................... Corn, pop, grain .......................... Corn, sweet, kernel plus cob with husks removed ................ Cotton, undelinted seed ............. Egg ............................................. Fruit, citrus, group 10–10 ........... Goat, fat ...................................... Goat, meat .................................. Goat, meat byproducts ............... Hog, fat ....................................... Hog, meat ................................... Horse, fat .................................... Horse, meat ................................ Horse, meat byproducts ............. Milk, fat, reflecting 0.10 ppm in whole milk ............................... Nut, tree, group 14–12 ............... Pea and bean, dried shelled, except soybean, subgroup 6C .... Pea and bean, succulent shelled, subgroup 6B .............. Poultry, fat .................................. Poultry, meat .............................. Rice, grain .................................. Sheep, fat ................................... Sheep, meat ............................... Sheep, meat byproducts ............ Sorghum, grain, grain ................. Soybean, seed ............................ Vegetable, cucurbit, group 9 ...... Vegetable, fruiting, group 8–10 .. Vegetable, leafy, group 4 ........... Vegetable, legume, edible podded, subgroup 6A ................... Vegetable, root and tuber, group 1, except sugar beet ............... Wheat, grain ............................... * (a) * * * (3) Tolerances are established for residues of the insecticide, alphacypermethrin, (R)-cyano(3phenoxyphenyl)methyl (1S,3S)-rel-3(2,2-dichloroethenyl)-2,2dimethylcyclopropane carboxylate, including its metabolites and degradates, in or on the commodities in the table below. Compliance with the tolerance levels specified below is to be determined by measuring only total cypermethrin, cyano(3phenoxyphenyl)methyl 3-(2,2dichloroethenyl)-2,2dimethylcyclopropane carboxylate, in or on the commodity. Parts per million Commodity * * * 0.20 2.0 1.0 0.20 0.05 1.8 4.0 0.05 0.05 0.05 0.50 0.05 10 1.0 0.20 0.05 1.0 0.05 1.0 0.20 0.05 2.5 0.05 0.05 0.10 0.05 0.05 1.5 1.0 0.20 0.05 0.50 0.05 0.20 0.20 10 0.50 0.10 0.20 * [FR Doc. 2013–02206 Filed 1–31–13; 8:45 am] BILLING CODE 6560–50–P 40 CFR Part 180 [EPA–HQ–OPP–2012–0789; FRL–9376–1] 2-Pyrrolidone, 1-Ethenyl-, Polymer With Ethenol; Tolerance Exemption Environmental Protection Agency (EPA). ACTION: Final rule. AGENCY: This regulation establishes an exemption from the requirement of a tolerance for residues of 2-pyrrolidone, 1-ethenyl-, polymer with ethenol; when used as an inert ingredient in a pesticide formulation. Sekisui Specialty SUMMARY: Frm 00019 Fmt 4700 Chemicals America, LLC submitted a petition to EPA under the Federal Food, Drug, and Cosmetic Act (FFDCA), requesting an exemption from the requirement of a tolerance. This regulation eliminates the need to establish a maximum permissible level for residues of 2-pyrrolidone, 1-ethenyl-, polymer with ethenol on food or feed commodities. DATES: This regulation is effective February 1, 2013. Objections and requests for hearings must be received on or before April 2, 2013, and must be filed in accordance with the instructions provided in 40 CFR part 178 (see also Unit I.C. of the SUPPLEMENTARY INFORMATION). The docket for this action, identified by docket identification (ID) number EPA–HQ–OPP–2012–0789, is available at https://www.regulations.gov or at the Office of Pesticide Programs Regulatory Public Docket (OPP Docket) in the Environmental Protection Agency Docket Center (EPA/DC), EPA West Bldg., Rm. 3334, 1301 Constitution Ave. NW., Washington, DC 20460–0001. The Public Reading Room is open from 8:30 a.m. to 4:30 p.m., Monday through Friday, excluding legal holidays. The telephone number for the Public Reading Room is (202) 566–1744, and the telephone number for the OPP Docket is (703) 305–5805. Please review the visitor instructions and additional information about the docket available at https://www.epa.gov/dockets. FOR FURTHER INFORMATION CONTACT: David Lieu, Registration Division (7505P), Office of Pesticide Programs, Environmental Protection Agency, 1200 Pennsylvania Ave. NW., Washington, DC 20460–0001; telephone number: (703) 305–0079; email address: Lieu.David@epa.gov. ADDRESSES: SUPPLEMENTARY INFORMATION: ENVIRONMENTAL PROTECTION AGENCY PO 00000 7275 Sfmt 4700 I. General Information A. Does this action apply to me? You may be potentially affected by this action if you are an agricultural producer, food manufacturer, or pesticide manufacturer. The following list of North American Industrial Classification System (NAICS) codes is not intended to be exhaustive, but rather provides a guide to help readers determine whether this document applies to them. Potentially affected entities may include: • Crop production (NAICS code 111). • Animal production (NAICS code 112). • Food manufacturing (NAICS code 311). E:\FR\FM\01FER1.SGM 01FER1

Agencies

[Federal Register Volume 78, Number 22 (Friday, February 1, 2013)]
[Rules and Regulations]
[Pages 7266-7275]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-02206]


=======================================================================
-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 180

[EPA-HQ-OPP-2010-0234; FRL-9376-1]


Alpha-Cypermethrin; Pesticide Tolerances

AGENCY: Environmental Protection Agency (EPA).

ACTION: Final rule.

-----------------------------------------------------------------------

SUMMARY: This regulation establishes tolerances for residues of alpha-
cypermethrin, in or on multiple commodities which are identified and 
discussed later in this document. BASF Corporation requested these 
tolerances under the Federal Food, Drug, and Cosmetic Act (FFDCA).

DATES: This regulation is effective February 1, 2013. Objections and 
requests for hearings must be received on or before April 2, 2013, and 
must be filed in accordance with the instructions provided in 40 CFR 
part 178 (see also Unit I.C. of the SUPPLEMENTARY INFORMATION).

ADDRESSES: The docket for this action, identified by docket 
identification (ID) number EPA-HQ-OPP-2010-0234, is available at https://www.regulations.gov or at the Office of Pesticide Programs Regulatory 
Public Docket (OPP Docket) in the Environmental Protection Agency 
Docket Center (EPA/DC), EPA West Bldg., Rm. 3334, 1301 Constitution 
Ave. NW., Washington, DC 20460-0001. The Public Reading Room is open 
from 8:30 a.m. to 4:30 p.m., Monday through Friday, excluding legal 
holidays. The telephone number for the Public Reading Room is (202) 
566-1744, and the telephone number for the OPP Docket is (703) 305-
5805. Please review the visitor instructions and additional information 
about the docket available at https://www.epa.gov/dockets.

FOR FURTHER INFORMATION CONTACT: BeWanda Alexander, Registration 
Division (7505P), Office of Pesticide Programs, Environmental 
Protection Agency, 1200 Pennsylvania Ave. NW., Washington, DC 20460-
0001; telephone number: (703) 305-7460; email address: 
alexander.bewanda@epa.gov.

SUPPLEMENTARY INFORMATION:

I. General Information

A. Does this action apply to me?

    You may be potentially affected by this action if you are an 
agricultural producer, food manufacturer, or pesticide manufacturer. 
The following list of North American Industrial Classification System 
(NAICS) codes is not intended to be exhaustive, but rather provides a 
guide to help readers determine whether this document applies to them. 
Potentially affected entities may include:
     Crop production (NAICS code 111).
     Animal production (NAICS code 112).
     Food manufacturing (NAICS code 311).
     Pesticide manufacturing (NAICS code 32532).

B. How can I get electronic access to other related information?

    You may access a frequently updated electronic version of EPA's 
tolerance regulations at 40 CFR part 180 through the Government 
Printing Office's e-CFR site at https://ecfr.gpoaccess.gov/cgi/t/text/text-idx?&c=ecfr&tpl=/ecfrbrowse/Title40/40tab_02.tpl.

C. How can I file an objection or hearing request?

    Under FFDCA section 408(g), 21 U.S.C. 346a, any person may file an 
objection to any aspect of this regulation and may also request a 
hearing on those objections. You must file your objection or request a 
hearing on this regulation in accordance with the instructions provided 
in 40 CFR part 178. To ensure proper receipt by EPA, you must identify 
docket ID number EPA-HQ-OPP-2010-0234 in the subject line on the first 
page of your submission. All objections and requests for a hearing must 
be in writing, and must be received by the Hearing Clerk on or before 
April 2, 2013. Addresses for mail and hand delivery of objections and 
hearing requests are provided in 40 CFR 178.25(b).
    In addition to filing an objection or hearing request with the 
Hearing Clerk as described in 40 CFR part 178, please submit a copy of 
the filing (excluding any Confidential Business Information (CBI)) for 
inclusion in the public docket. Information not marked confidential 
pursuant to 40 CFR part 2 may be disclosed publicly by EPA without 
prior notice. Submit the non-CBI copy of your objection or hearing 
request, identified by docket ID number EPA-HQ-OPP-2010-0234, by one of 
the following methods:
     Federal eRulemaking Portal: https://www.regulations.gov. 
Follow the online instructions for submitting comments. Do not submit 
electronically any information you consider to be CBI or other 
information whose disclosure is restricted by statute.
     Mail: OPP Docket, Environmental Protection Agency Docket 
Center (EPA/DC), (28221T), 1200 Pennsylvania Ave. NW., Washington, DC 
20460-0001.
     Hand Delivery: To make special arrangements for hand 
delivery or delivery of boxed information, please follow the 
instructions at https://www.epa.gov/dockets/contacts.htm.
    Additional instructions on commenting or visiting the docket, along 
with more information about dockets generally, is available at https://www.epa.gov/dockets.

II. Summary of Petition-For Tolerance

    In the Federal Register of May 19, 2010 (75 FR 28009) (FRL-8823-2), 
EPA issued a document pursuant to FFDCA section 408(d)(3), 21 U.S.C. 
346a(d)(3), announcing the filing of a pesticide petition (PP 0F7690) 
by BASF Corporation, 26 Davis Drive, P.O. Box 13528, Research Triangle 
Park, NC 27709-3528. The petition requested that 40 CFR 180.418 be 
amended by

[[Page 7267]]

establishing tolerances for residues of the insecticide alpha-
cypermethrin in or on tree nuts, Group 14; dried shelled pea and bean, 
except soybean, subgroup 6C; corn, grain; pop corn; sweet corn; 
soybeans; and sugar beet, roots at 0.05 parts per million (ppm); 
succulent shelled pea and bean, subgroup 6B; and root and tuber 
vegetables, Group 1 at 0.1 ppm; cucurbit vegetables, Group 9; fruiting 
vegetables, Group 8; sugar beet, tops; and wheat, grain at 0.2 ppm; 
citrus fruit, Group 10 at 0.35 ppm; cottonseed; edible podded legume 
vegetable, subgroup 6A; and sorghum, grain at 0.5 ppm; and rice, grain 
at 1.5 ppm; citrus, dried pulp at 1.8 ppm; head and stem Brassica, 
subgroup 5A at 2.0 ppm; citrus, oil at 4.0 ppm; leafy vegetable, except 
Brassica, Group 4 at 10 ppm; and alfalfa, hay at 15 ppm. There were no 
comments received in response to the notice of filing.
    Based upon review of the data supporting the petition, EPA has 
established tolerances for alpha-cypermethrin ((R)-cyano(3-
phenoxyphenyl)methyl (1S,3S)-rel-3-(2,2-dichloroethenyl)-2,2-
dimethylcyclopropane carboxylate) as explained in Unit IV.D.

III. Aggregate Risk Assessment and Determination of Safety

    Section 408(b)(2)(A)(i) of FFDCA allows EPA to establish a 
tolerance (the legal limit for a pesticide chemical residue in or on a 
food) only if EPA determines that the tolerance is ``safe.'' Section 
408(b)(2)(A)(ii) of FFDCA defines ``safe'' to mean that ``there is a 
reasonable certainty that no harm will result from aggregate exposure 
to the pesticide chemical residue, including all anticipated dietary 
exposures and all other exposures for which there is reliable 
information.'' This includes exposure through drinking water and in 
residential settings, but does not include occupational exposure. 
Section 408(b)(2)(C) of FFDCA requires EPA to give special 
consideration to exposure of infants and children to the pesticide 
chemical residue in establishing a tolerance and to ``ensure that there 
is a reasonable certainty that no harm will result to infants and 
children from aggregate exposure to the pesticide chemical residue. * * 
*''
    Consistent with FFDCA section 408(b)(2)(D), and the factors 
specified in FFDCA section 408(b)(2)(D), EPA has reviewed the available 
scientific data and other relevant information in support of this 
action. EPA has sufficient data to assess the hazards of and to make a 
determination on aggregate exposure for alpha-cypermethrin including 
exposure resulting from the tolerances established by this action. 
EPA's assessment of exposures and risks associated with alpha-
cypermethrin follows.

A. Toxicological Profile

    EPA has evaluated the available toxicity data and considered its 
validity, completeness, and reliability as well as the relationship of 
the results of the studies to human risk. EPA has also considered 
available information concerning the variability of the sensitivities 
of major identifiable subgroups of consumers, including infants and 
children.
    Alpha-cypermethrin, cypermethrin, and zeta-cypermethrin are all 
pyrethroid insecticides and are isomer mixtures of the same chemical. 
The cypermethrins have been evaluated for a variety of toxic effects in 
experimental toxicity studies. Behavioral changes commonly seen with 
type II pyrethroids were consistently noted in the toxicology database 
for the cypermethrins. These behavioral changes included tremors, gait 
abnormalities, limb conditions, ataxia and hypersensitivity. 
Additionally, body weight changes were routinely observed and mortality 
was seen in a few studies in rats and dogs. Clinical signs were also 
noted in all acute neurotoxicity studies. Decreased activity, gait 
abnormalities, tremors, limb conditions, and hypersensitivity were 
observed at the mid and high doses. Additionally, slight nerve 
degeneration was seen in the acute neurotoxicity study with alpha-
cypermethrin at the high dose. In the subchronic neurotoxicity studies 
with cypermethrin and zeta-cypermethrin, similar behavioral effects 
were seen along with decreased food consumption, body weight, and body 
weight gain.
    Acute toxicology studies conducted with cypermethrins indicate 
moderate acute toxicity via the oral route and low toxicity via the 
acute dermal or inhalation routes. Additionally, mild irritation was 
seen in primary eye and skin irritation studies but no dermal 
sensitization was observed.
    Dermal toxicity studies are available for zeta-cypermethrin (rat) 
and cypermethrin (rabbit), in which local irritation was observed in 
rats and rabbits at the highest doses tested. No systemic effects were 
observed in the 21-day dermal study in the rat conducted with zeta-
cypermethrin at dose levels up to 1,000 milligrams/kilogram/day (mg/kg/
day). In the dermal toxicity study in rabbits with cypermethrin, 
systemic effects were observed (focal necrosis of the liver, decreased 
testicular weights, and decreased body weight in females). However, 
these observations in the rabbit were not used for risk assessment 
because the testing method (i.e., abraded skin) does not simulate 
actual exposure and results in compromised test conditions. 
Additionally, there would be physiological differences between abraded 
and non-abraded animals, further undermining the relevance of these 
results for risk assessment.
    Developmental toxicity and reproduction studies are available for 
the cypermethrins. In the developmental toxicity studies in rats with 
cypermethrin and zeta-cypermethrin, there was no evidence of 
developmental toxicity up to the highest doses tested. Maternal 
toxicity included decreased body weight gain and food consumption in 
both chemicals. Splayed limbs, spasms and hypersensitivity to noise and 
convulsions were seen with cypermethrin, and ataxia, urine-stained 
abdominal fur, and fecal-stained fur were seen with zeta-cypermethrin. 
In the developmental toxicity study in rats with alpha-cypermethrin, 
offspring effects were limited to decreased fetal body weight. Maternal 
effects observations in the study were unsteady gait, piloerection, 
limb splay, and hypersensitivity to sound and touch at the same dose. 
In the developmental toxicity studies in rabbits with the 
cypermethrins, there was no evidence of developmental toxicity up to 
the highest dose tested. Maternal effects seen with cypermethrin 
included decreased body weight gain, anorexia, abdomino-genital 
staining, decreased feces, and red or pink material in the pan. With 
alpha-cypermethrin, maternal effects were body weight loss and 
decreased food consumption. Multi-generation reproduction studies in 
rats are available for cypermethrin and zeta-cypermethrin. In the 
reproduction study with cypermethrin, decreased body weight gain was 
observed in adult animals and decreased body weight gain was seen in 
offspring animals at the highest dose tested. In the reproduction study 
using zeta-cypermethrin, decreased body weight gain and mortality were 
observed in offspring animals in the presence of mortality, increased 
brain weights, decreased body weights, and neurotoxicity in maternal 
animals.
    No effects were observed in an immunotoxicity study in rats with 
alpha-cypermethrin up to the limit dose.
    Alpha-cypermethrin is classified as a Group C ``Possible human 
carcinogen,'' based on an increased incidence of lung adenomas and 
adenomas plus carcinomas combined in females in a mouse carcinogenicity 
study. The

[[Page 7268]]

presence of common benign tumors (lung adenomas), in one species (mice) 
and one sex (female), with no increase in the proportion of malignant 
tumors or decrease in the time-to-tumor occurrence, together with the 
lack of mutagenic activity, was not considered strong enough to warrant 
a quantitative estimation of human risk. Quantification of risk using a 
non-linear approach (i.e., acute population-adjusted dose (aPAD), acute 
reference dose (aRfD)) adequately accounts for all chronic toxicity, 
including carcinogenicity that could result from exposure to alpha-
cypermethrin. While the Agency would typically use a chronic 
population-adjusted dose (cPAD) to protect for cancer concerns, use of 
the aPAD is protective because increasing toxicity with increasing 
duration of exposure is not demonstrated for the cypermethrins. The no-
observed-adverse-effect-level (NOAEL) observed in the mouse cancer 
study in which tumors were observed is 14 mg/kg/day, 2-fold higher than 
the point of departure (POD) used for acute risk assessment. The 
lowest-observed-adverse-effect-level (LOAEL) in the mouse cancer study 
is 57 mg/kg/day based on liver effects, not tumor formation. The tumors 
were seen at 229 mg/kg/day. The acute POD of 7.16 mg/kg/day selected 
for risk assessment is 32-fold lower than the dose that induced lung 
tumors in mice. Only the mouse study with cypermethrin resulted in 
tumor formation, no evidence of carcinogenicity was observed in cancer 
studies in rats with cypermethrin or mice with alpha-cypermethrin.
    Specific information on the studies received and the nature of the 
adverse effects caused by chemical name as well as the NOAEL and the 
LOAEL from the toxicity studies can be found at https://www.regulations.gov in document Human Health Risk Assessment for New 
Active Ingredient--Alpha-cypermethrin at pg. 23 in docket ID number 
EPA-HQ-OPP-2012-0185-0005.

B. Toxicological Points of Departure and Levels of Concern

    Once a pesticide's toxicological profile is determined, EPA 
identifies toxicological POD and levels of concern (LOC) to use in 
evaluating the risk posed by human exposure to the pesticide. For 
hazards that have a threshold below which there is no appreciable risk, 
the toxicological POD is used as the basis for derivation of reference 
values for risk assessment. PODs are developed based on a careful 
analysis of the doses in each toxicological study to determine the dose 
at which no adverse effects are observed and the lowest dose at which 
adverse effects of concern are identified. Uncertainty/safety factors 
are used in conjunction with the POD to calculate a safe exposure 
level--generally referred to as a PAD or a reference dose (RfD)--and a 
safe margin of exposure (MOE). For non-threshold risks, EPA assumes 
that any amount of exposure will lead to some degree of risk. Thus, the 
Agency estimates risk in terms of the probability of an occurrence of 
the adverse effect expected in a lifetime. For more information on the 
general principles EPA uses in risk characterization and a complete 
description of the risk assessment process, see https://www.epa.gov/pesticides/factsheets/riskassess.htm.
    A summary of the toxicological endpoints for alpha-cypermethrin 
used for human risk assessment is shown in Table 1 of this unit.

    Table 1--Summary of Toxicological Doses and Endpoints for Alpha-Cypermethrin for Use in Human Health Risk
                                                   Assessment
----------------------------------------------------------------------------------------------------------------
                                   POD and uncertainty/   RfD, PAD, LOC for
        Exposure/Scenario             safety factors       risk assessment      Study and toxicological effects
----------------------------------------------------------------------------------------------------------------
Acute dietary (children >=6 years  Wolansky MDL1SD =     aRfD = 0.07 mg/kg/   Wolansky BMD = 11.20 mg/kg/day
 old and adults).                   7.16 mg/kg/day.       day.                 based on motor activity.
                                   UFA = 10x...........  aPAD = 0.07 mg/kg/
                                   UFH = 10x...........   day.
                                   FQPA SF = 1x........
Acute dietary (children <6 years   Wolansky BMDL1SD =    aRfD = 0.07 mg/kg/   Wolansky BMD = 11.20 mg/kg/day
 old).                              7.16 mg/kg/day.       day.                 based on motor activity.
                                   UFA = 10x...........  aPAD = 0.023 mg/kg/
                                   UFH = 10x...........   day.
                                   FQPA SF = 3x........
                                  ------------------------------------------------------------------------------
Chronic dietary (All populations)      Because of the rapid reversibility of the most sensitive neurotoxicity
                                      endpoint used for quantifying risks, there is no increase in hazard with
                                       increasing dosing duration, and therefore the acute dietary endpoint is
                                                          protective for chronic exposure.
                                  ------------------------------------------------------------------------------
Incidental oral short-term (1 to   Wolansky BMDL1SD =    LOC for MOE = 300..  Wolansky BMD = 11.20 mg/kg/day
 30 days).                          7.16 mg/kg/day.                            based on motor activity.
                                   UFA = 10x...........
                                   UFH = 10x...........
                                   FQPA SF = 3x........
Inhalation short-term (1 to 30     Inhalation study....  Residential LOC for  21-day inhalation study in the
 days) (children <6 years old).    NOAEL = 0.01 mg/L...   MOE = 100.           rat--LOAEL = .05 mg/L based on
                                   HEC = 0.008 mg/L....                        increased salivation.
                                   HED = 1.15 mg/kg/day
                                   UFA = 3x............
                                   UFH = 10x...........
                                   FQPA SF = 3x........

[[Page 7269]]

 
Inhalation short-term (1 to 30     Inhalation study      LOC for MOE = 30...  21-day inhalation study in the
 days) (children >=6 years old      NOAEL = 0.01 mg/L.                         rat--LOAEL = 0.05 mg/L based on
 and adults) (1 to 6 months).      HEC = 0.008 mg/L....                        increased salvation.
                                   HED = 1.15 mg//kg/
                                    day.
                                   UFA = 3x............
                                   UFH = 10x...........
                                   FQPA SF = 1x........
                                  ------------------------------------------------------------------------------
Cancer (Oral, dermal, inhalation)       Alpha cypermethrin has been classified as a Group C ``Possible human
                                       carcinogen based on lung adenomas in female mice. Because of the rapid
                                         reversibility of the most sensitive neurotoxicity endpoint used for
                                      quantifying risks, there is no increase in hazard with increasing dosing
                                        duration. Therefore, the acute dietary endpoint is protective of the
                                      endpoints from repeat dosing studies, including cancer dietary exposures.
----------------------------------------------------------------------------------------------------------------

    Point of Departure (POD) = A data point or an estimated point that 
is derived from observed dose-response data and used to mark the 
beginning of extrapolation to determine risk associated with lower 
environmentally relevant human exposures. NOAEL = no observed adverse 
effect level. LOAEL = lowest observed adverse effect level. BMD = 
benchmark dose. BMDL = benchmark dose (lower confidence limit). UF = 
uncertainty factor. UFA = extrapolation from animal to human 
(interspecies). UFH = potential variation in sensitivity among members 
of the human population (intraspecies). FQPA SF = FQPA Safety Factor. 
PAD = population adjusted dose (a = acute, c = chronic). RfD = 
reference dose. MOE = margin of exposure. LOC = level of concern. N/A = 
not applicable. HEC = human equivalent concentration. HED = human 
equivalent dose. Mg/kg/day = milligrams/kilogram/day. Mg/L = 
milligrams/liter.

C. Exposure Assessment

    1. Dietary exposure from food and feed uses. In evaluating dietary 
exposure to alpha-cypermethrin, EPA considered exposure under the 
petitioned-for tolerances as well as all existing cypermethrin and 
zeta-cypermethrin tolerances in 40 CFR 180.418. EPA assessed dietary 
exposures from alpha-cypermethrin in food as follows:
    i. Acute exposure. Quantitative acute dietary exposure and risk 
assessments are performed for a food-use pesticide, if a toxicological 
study has indicated the possibility of an effect of concern occurring 
as a result of a 1-day or single exposure. Such effects were identified 
for alpha-cypermethrin.
    In assessing aggregate risk to alpha-cypermethrin, EPA considered 
not only the exposure associated with the proposed food uses for alpha-
cypermethrin, but also the potential dietary and drinking water 
contribution and residential exposure from existing uses of 
cypermethrin and zeta-cypermethrin. In estimating acute dietary 
exposure, EPA used food consumption information from the U.S. 
Department of Agriculture (USDA) 1994-1996 and 1998 Nationwide 
Continuing Surveys of Food Intake by Individuals (CSFII). As to residue 
levels in food, EPA used a partially refined (probabilistic) dietary 
exposure assessment to determine the exposure and risk estimates which 
result from the use of cypermethrins on the crops listed under 40 CFR 
180.418 and the proposed new uses. Anticipated residues from USDA 
Pesticide Data Program (PDP) monitoring data, field trial data, and 
empirical processing factors, and percent crop treated (PCT) estimates 
for some commodities were used where appropriate.
    ii. Chronic exposure. Based on the data summarized in Unit III.A., 
there is no increase in hazard from repeated exposures to alpha-
cypermethrin; the acute dietary exposure assessment is higher than for 
chronic dietary exposures because the acute exposure levels are greater 
than the chronic exposure levels, therefore, a chronic dietary risk 
assessment was not conducted.
    iii. Cancer. As noted in Unit III.A., the Agency has determined 
that quantification of risk using a non-linear approach (i.e., aPAD) 
will adequately account for all chronic toxicity, including 
carcinogenicity, that could result from exposure to alpha-cypermethrin. 
Additionally, because an assessment of cancer risk would estimate 
exposure based on average residue levels and the acute assessment used 
high-end residue levels, the acute dietary assessment will be 
protective of any cancer effects resulting from consumption of alpha-
cypermethrin residues in foods.
    iv. Anticipated residue and PCT information. Section 408(b)(2)(E) 
of FFDCA authorizes EPA to use available data and information on the 
anticipated residue levels of pesticide residues in food and the actual 
levels of pesticide residues that have been measured in food. If EPA 
relies on such information, EPA must require pursuant to FFDCA section 
408(f)(1) that data be provided 5 years after the tolerance is 
established, modified, or left in effect, demonstrating that the levels 
in food are not above the levels anticipated. For the present action, 
EPA will issue such Data Call-Ins as are required by FFDCA section 
408(b)(2)(E) and authorized under FFDCA section 408(f)(1). Data will be 
required to be submitted no later than 5 years from the date of 
issuance of these tolerances demonstrating that the levels in food are 
not above the levels anticipated.
    Section 408(b)(2)(F) of FFDCA states that the Agency may use data 
on the actual percent of food treated for assessing chronic dietary 
risk only if:
     Condition a: The data used are reliable and provide a 
valid basis to show what percentage of the food derived from such crop 
is likely to contain the pesticide residue.
     Condition b: The exposure estimate does not underestimate 
exposure for any significant subpopulation group.
     Condition c: Data are available on pesticide use and food 
consumption in a particular area, the exposure estimate does not 
understate exposure for the population in such area.

[[Page 7270]]

    In addition, the Agency must provide for periodic evaluation of any 
estimates used. To provide for the periodic evaluation of the estimate 
of PCT as required by FFDCA section 408(b)(2)(F), EPA may require 
registrants to submit data on PCT. The following maximum PCT estimates 
were used in the acute dietary risk assessment, which was relied on in 
assessing chronic risk, for the following crops that are currently 
registered for the cypermethrins: Almonds, 2.5%; apples, 2.5%; 
broccoli, 30%; cabbage, 30%; carrot, 10%; cauliflower, 25%; celery, 
60%; cherries, 5%; grapefruit, 50%; green beans, 20%; green peas, 15%; 
lemon, 2.5%; lettuce, 65%; orange, 45%; peach, 5%; peppers, 30%; 
potato, 5%; sweet corn, 20%; spinach, 45%; tomato, 10%; and watermelon, 
10%.
    The following average PCT estimates were used to calculate average 
dietary exposures in order to assess short-term aggregate risk to the 
cypermethrins: Almonds, 1%; apples, 1%; broccoli, 20%; cabbage, 15%; 
carrot, 2.5%; cauliflower, 15%; celery, 35%; cherries, 5%; grapefruit, 
35%; green beans, 15%; green peas, 10%; lemon, 1%; lettuce, 55%; 
orange, 35%; peach, 2.5%; peppers, 15%; potato, 1%; sweet corn, 15%; 
spinach, 30%; tomato, 5%; and watermelon, 2.5%. The zeta-cypermethrin 
PCT data was used as a surrogate for future PCT of alpha-cypermethrin.
    In most cases, EPA uses available data from the U.S. Department of 
Agriculture/National Agricultural Statistics Service (USDA/NASS), 
proprietary market surveys, and the National Pesticide Use Database for 
the chemical/crop combination for the most recent 6-7 years. EPA uses 
an average PCT for chronic dietary risk analysis. The average PCT 
figure for each existing use is derived by combining available public 
and private market survey data for that use, averaging across all 
observations, and rounding to the nearest 5%, except for those 
situations in which the average PCT is less than 1. In those cases, 1% 
is used as the average PCT and 2.5% is used as the maximum PCT. EPA 
uses a maximum PCT for acute dietary risk analysis. The maximum PCT 
figure is the highest observed maximum value reported within the recent 
6 years of available public and private market survey data for the 
existing use and rounded up to the nearest multiple of 5%.
    The Agency believes that the three conditions discussed in Unit 
III.C.1.iv. have been met. With respect to Condition a, PCT estimates 
are derived from Federal and private market survey data, which are 
reliable and have a valid basis. The Agency is reasonably certain that 
the percentage of the food treated is not likely to be an 
underestimation. As to Conditions b and c, regional consumption 
information and consumption information for significant subpopulations 
is taken into account through EPA's computer-based model for evaluating 
the exposure of significant subpopulations including several regional 
groups. Use of this consumption information in EPA's risk assessment 
process ensures that EPA's exposure estimate does not understate 
exposure for any significant subpopulation group and allows the Agency 
to be reasonably certain that no regional population is exposed to 
residue levels higher than those estimated by the Agency. Other than 
the data available through national food consumption surveys, EPA does 
not have available reliable information on the regional consumption of 
food to which alpha-cypermethrin may be applied in a particular area.
    2. Dietary exposure from drinking water. The Agency used screening 
level water exposure models in the dietary exposure analysis and risk 
assessment for alpha-cypermethrin in drinking water. These simulation 
models take into account data on the physical, chemical, and fate/
transport characteristics of alpha-cypermethrin. Further information 
regarding EPA drinking water models used in pesticide exposure 
assessment can be found at https://www.epa.gov/oppefed1/models/water/index.htm.
    Based on the First Index Reservoir Screening Tool (FIRST) and 
Screening Concentration in Ground Water (SCI-GROW) models the estimated 
drinking water concentrations (EDWCs) of alpha-cypermethrin were 3.77 
parts per billion (ppb) for surface water and 0.0036 ppb for ground 
water. In the dietary risk assessment conducted to support the proposed 
uses, EPA incorporated the surface water EDWCs directly into the 
dietary model, since surface water estimates were higher than those 
provided for ground water.
    3. From non-dietary exposure. The term ``residential exposure'' is 
used in this document to refer to non-occupational, non-dietary 
exposure (e.g., for lawn and garden pest control, indoor pest control, 
termiticides, and flea and tick control on pets). Alpha-cypermethrin is 
not registered for any specific use patterns that would result in 
residential exposure. There are no proposed residential uses associated 
with alpha-cypermethrin; however, there are registered residential uses 
for cypermethrin and zeta-cypermethrin that have been reassessed to 
reflect updates to the Agency's 2012 Residential standard operating 
procedures (SOPs) along with policy changes for body weight assumptions 
and inhalation rates. These revised residential exposures have been 
incorporated into the human health aggregate risk assessment for alpha-
cypermethrin, which must consider all potential exposures to the 
cypermethrins. The Agency has determined that short-term exposures are 
likely to occur in a residential setting for the cypermethrins; 
however, they do not increase in potency with repeated dosing. EPA 
assessed residential exposure using the following assumptions. The 
quantitative exposure/risk assessment developed for residential 
handlers is based on the following scenarios:
     Mixer/loader/applicator using hose-end sprayer on turf;
     Mixer/loader/applicator using backpack on turf and 
gardens;
     Mixer/loader/applicator using manually pressurized 
handwand for indoor surfaces;
     Application via aerosol can for indoor surfaces and space.
    Since a dermal endpoint was not identified, only a quantitative 
inhalation handler exposure assessment was performed. Residential 
handler inhalation exposure estimates were calculated based on a human 
equivalent concentration and human equivalent dose which reflect 24 
hours of exposure. Since handler exposure is expected to be 
significantly less than 24 hours, the inhalation exposure estimates are 
sufficiently protective of all scenarios (turf, gardens, and indoor 
surface space). Although there is potential inhalation exposure 
resulting from the application of dog tags and spot-on products for 
pets, inhalation exposure is considered negligible for these scenarios 
and therefore a quantitative assessment was not performed for these 
uses.
    There is the potential for post-application exposure for 
individuals as a result of being in an environment that has been 
previously treated with cypermethrin or zeta-cypermethrin. However, the 
combination of low vapor pressure for chemicals typically used as 
active ingredients in outdoor residential pesticide products and 
dilution in outdoor air is likely to result in minimal inhalation 
exposure. Therefore, a quantitative post-application inhalation 
exposure assessment for cypermethrin turf uses was not conducted. Since 
a dermal endpoint was not identified, and indoor post-application 
inhalation exposure resulting from aerosol space sprays, foggers, and 
pet (i.e., dog tag, spot-on) uses is negligible, the only

[[Page 7271]]

potential post-application exposure pathways of concern are incidental 
oral for children, and post-application inhalation exposure for adults 
and children resulting from indoor crack and crevice applications made 
with a manually pressurized handwand. The quantitative exposure/risk 
assessment for residential post-application exposures is based on the 
following scenarios:
     Incidental oral (hand-to-mouth, object-to-mouth, and soil 
ingestion) exposure from turf for children.
     Incidental oral (hand-to-mouth and object-to-mouth) 
exposure from indoor foggers for children.
     Incidental oral (hand-to-mouth and object-to-mouth) 
exposure from pets for children.
     Inhalation exposure for adults and children resulting from 
crack and crevice application to an indoor surface.
     Incidental oral (hand-to-mouth and object-to-mouth) 
exposure for children from indoor surface applications.
    Risk estimates resulting from different exposure routes may be 
combined when it is likely that they can occur simultaneously based on 
the use pattern and when the toxicological effects across different 
routes of exposure are the same. Although, in the case of children, 
inhalation and incidental oral exposure routes share a common 
toxicological endpoint, risk estimates were not combined for those 
routes for turf, indoor fogger, and pet since post-application 
inhalation exposure is considered negligible. However, inhalation and 
incidental oral exposures were combined for post-application risk 
assessment associated with the indoor crack and crevice use. Inhalation 
and incidental oral routes have different LOCs. Therefore, in order to 
combine exposure from the various routes, the aggregate risk index 
(ARI) approach is used to estimate exposure and risk. When this 
approach is used, aggregate risks are not of concern provided the 
calculated ARI is greater than 1.
    The incidental oral scenarios from indoor exposure following crack 
and crevice applications and outdoor exposure from turf were not 
combined, not only because they are not likely to co-occur, but also 
because combining these scenarios would be overly-conservative due to 
the conservative nature of each of the individual assessments.
    Further information regarding EPA standard assumptions and generic 
inputs for residential exposures may be found at https://www.epa.gov/pesticides/trac/science/trac6a05.pdf.
    4. Cumulative effects from substances with a common mechanism of 
toxicity. Section 408(b)(2)(D)(v) of FFDCA requires that, when 
considering whether to establish, modify, or revoke a tolerance, the 
Agency consider ``available information'' concerning the cumulative 
effects of a particular pesticide's residues and ``other substances 
that have a common mechanism of toxicity.''
    The Agency is required to consider the cumulative risks of 
chemicals sharing a common mechanism of toxicity. The Agency has 
determined that the pyrethroids and pyrethrins, including the 
cypermethrins, share a common mechanism of toxicity. The members of 
this group share the ability to interact with voltage-gated sodium 
channels, ultimately leading to neurotoxicity. The cumulative risk 
assessment for the pyrethroids and pyrethrins was published in the 
Federal Register on November 9, 2011 (76 FR 69726) (FRL-8888-9), and is 
available at https://www.regulations.gov in the public docket, EPA-HQ-
OPP-2011-0746. Further information about the determination that 
pyrethroids and pyrethrins share a common mechanism of toxicity may be 
found in document ID: EPA-HQ-OPP-2008-0489-0006.
    The cypermethrins were included in a recent cumulative risk 
assessment for pyrethrins and pyrethroids. The proposed new uses of 
alpha-cypermethrin will not significantly impact the cumulative 
assessment because, in the cumulative assessment, residential exposure 
was the greatest contributor to the total exposure. There are no new 
residential uses for the cypermethrins, and the proposed new uses will 
have no impact on the residential component of the cumulative risk 
estimates.
    Dietary exposures make a minor contribution to total pyrethroid 
exposure. The dietary exposure assessment performed in support of the 
pyrethroid cumulative was much more highly refined than that performed 
for the single chemical. The dietary exposure assessment for the single 
chemical included conservative assumptions, using field trial data for 
many commodities, including the proposed new uses, with the assumption 
of 100 PCT, and the most sensitive apical endpoint in the cypermethrins 
hazard database was selected to derive the POD. Additionally, the POD 
selected for alpha-cypermethrin is specific to the cypermethrins, 
whereas the POD selected for the cumulative assessment was based on-
common-mechanism-of-action data that are appropriate for all 20 
pyrethroids included in the cumulative assessment.
    For information regarding EPA's efforts to evaluate the risk of 
exposure to pyrethroids, refer to https://www.epa.gov/oppsrrd1/reevaluation/pyrethroids-pyrethrins.html.

D. Safety Factor for Infants and Children

    1. In general. Section 408(b)(2)(C) of FFDCA provides that EPA 
shall apply an additional tenfold (10X) margin of safety for infants 
and children in the case of threshold effects to account for prenatal 
and postnatal toxicity and the completeness of the database on toxicity 
and exposure unless EPA determines based on reliable data that a 
different margin of safety will be safe for infants and children. This 
additional margin of safety is commonly referred to as the Food Quality 
Protection Act (FQPA) Safety Factor (SF). In applying this provision, 
EPA either retains the default value of 10X, or uses a different 
additional safety factor when reliable data available to EPA support 
the choice of a different factor.
    2. Prenatal and postnatal sensitivity. In guideline developmental 
and reproduction studies with the cypermethrins, there was no evidence 
of increased qualitative or quantitative susceptibility in rats or 
rabbits.
    In a guideline developmental neurotoxicity (DNT) study with zeta-
cypermethrin, there was increased sensitivity in the offspring based on 
body weight changes in pups (5%-10%) in the absence of treatment-
related effects in maternal animals. Although, there was a 5%-8% 
decrease in maternal body weight in this study, a body weight decrease 
of <10% is generally not considered adverse in adults, as this is 
considered to be within the range of variability because the magnitude 
of body weight per se is typically small (as an example, a 3 gram (g) 
decrease in body weight from a 338 g rat), and adults are no longer in 
the growth/development phase. In contrast, the offspring are at a stage 
of growth and development and are therefore expected to be gaining 
rather than losing weight. Thus, a smaller percent decrease in body 
weight is considered adverse in the young relative to adults. In the 
case of zeta-cypermethrin, the decrease in body weight of the young is 
comparable to adults; however, it was considered adverse in the young 
but not in the adults. This disparity in interpretation leads to an 
apparent increase in sensitivity in the young; however, concern is 
reduced since the magnitude of body weight decrements was similar in 
adult and young animals. The results from the DNT study are very 
similar to results observed in the reproduction

[[Page 7272]]

studies where body weight (bwt) changes (decreased body weight gain) 
were seen in maternal and offspring animals at doses similar to those 
in the DNT study, with no indication of increased susceptibility. 
Therefore, there is no residual concern for effects observed in the 
study. Additionally, there are well-characterized dose responses, with 
clear NOAELs and LOAELs for effects seen in the DNT and reproduction 
studies, and the endpoints and PODs selected for risk assessment are 
protective.
    High-dose LD50 studies (studies assessing what dose 
results in lethality to 50% of the tested population) in the scientific 
literature indicate that pyrethroids can result in increased 
quantitative sensitivity in the young, typically in the form of 
neurotoxicity. Examination of pharmacokinetic and pharmacodynamic data 
indicates that the sensitivity observed at high doses is related to 
pyrethroid age-dependent pharmacokinetics--the activity of enzymes 
associated with the metabolism of pyrethroids. With otherwise 
equivalent administered doses for adults and juveniles, predictive 
pharmacokinetic models indicate that the differential adult-juvenile 
pharmacokinetics will result in a 3X greater dose at the target organ 
in juveniles compared to adults. No evidence of increased quantitative 
or qualitative susceptibility was seen in the pyrethroid scientific 
literature related to pharmacodynamics (the effect of pyrethroids at 
the target tissue) both with regard to inter-species differences 
between rats and humans and to differences between juveniles and 
adults. Specifically, there are in vitro pharmacodynamic data and in 
vivo data indicating similar responses between adult and juvenile rats 
at low doses and data indicating that the rat is a conservative model 
compared to the human based on species-specific pharmacodynamics of 
homologous sodium channel isoforms in rats and humans.
    3. Conclusion. The FQPA SF was reduced to 1X for the general 
population, women of child bearing age and children > 6 years. For 
exposures from birth to <6 years of age, a 3X FQPA SF was retained 
based on the following considerations:
    i. The toxicology database for the cypermethrins is not complete. 
While the database is considered to be complete with respect to the 
guideline toxicity studies for alpha-cypermethrin, EPA lacks additional 
data to fully characterize the potential for juvenile sensitivity to 
neurotoxic effects of pyrethroids. In light of the literature studies 
indicating a possibility of increased sensitivity to cypermethrins in 
juvenile rats at high doses, EPA has requested proposals for study 
protocols which could identify and quantify potential juvenile 
sensitivity. However, when evaluated together, the toxicity studies for 
the cypermethrins can be used to characterize toxic effects including 
potential developmental and reproductive toxicity, immunotoxicity, and 
neurotoxicity. Acceptable developmental toxicity studies in rats and 
rabbits, reproduction studies in rats, neurotoxicity studies (acute 
neurotoxicity (ACN), subchronic neurotoxicity (SCN), and DNT) in rats, 
and immunotoxicity studies in rats are available. In addition, route-
specific dermal and inhalation studies are available.
    ii. After reviewing the extensive body of data and peer-reviewed 
literature on pyrethroids, the Agency has reached a number of 
conclusions regarding fetal juvenile sensitivity for pyrethroids, 
including the following:
     Based on an evaluation of over 70 guideline toxicity 
studies for 24 pyrethroids submitted to the Agency, including prenatal 
developmental toxicity studies in rats and rabbits, and prenatal and 
postnatal multi-generation reproduction toxicity studies and DNTs in 
rats in support of pyrethroid registrations, there is no evidence that 
pyrethroids directly impact developing fetuses. None of the studies 
show any indications of fetal toxicity at doses that do not cause 
maternal toxicity.
     Increased susceptibility was seen in offspring animals in 
the DNT study with zeta-cypermethrin (decreased pup body weights) and 
DNT and reproduction studies with beta-cyfluthrin (decreased body 
weights and tremors). However, the reductions in body weight and the 
other non-specific effects occur at higher doses than neurotoxicity, 
the effect of concern for pyrethroids. The available developmental and 
reproduction guideline studies in rats with zeta-cypermethrin did not 
show increased sensitivity in the young to neurotoxic effects. Overall, 
findings of increased sensitivity in juvenile animals in pyrethroid 
studies are rare. Therefore, the residual concern for the postnatal 
effects is reduced.
     High-dose LD50 studies (studies assessing what 
dose results in lethality to 50% of the tested population) in the 
scientific literature indicate that pyrethroids can result in increased 
quantitative sensitivity to juvenile animals. Examination of 
pharmacokinetic and pharmacodynamic data indicates that the sensitivity 
observed at high doses is related to pyrethroid age-dependent 
pharmacokinetics--the activity of enzymes associated with the 
metabolism of pyrethroids. Furthermore, a rat PBPK model predicts a 
three-fold increase of pyrethroid concentration in juvenile brain 
compared to adults at high doses.
     In vitro pharmacodynamic data and in vivo data 
indicate that adult and juvenile rats have similar responses to 
pyrethroids at low doses and therefore juvenile sensitivity is not 
expected at relevant environmental exposures. Further, data also show 
that the rat is a conservative model compared to the human based on 
species-specific pharmacodynamics of homologous sodium channel 
isoforms.
    iii. There are no residual uncertainties with regard to dietary and 
residential exposure. The dietary exposure assessments are based on 
high-end health protective residue levels (that account for parent and 
metabolites of concern), processing factors, and PCT assumptions. 
Furthermore, conservative, upper-bound assumptions were used to 
determine exposure through drinking water and residential sources, such 
that these exposures have not been underestimated.
    Taking all of this information into account, EPA has reduced the 
FQPA SF for women of child-bearing age and children over 6 years to 1X 
since after evaluation of over 70 guideline toxicity studies submitted 
to the Agency, including prenatal developmental toxicity studies in 
rats and rabbits, and multi-generation reproduction toxicity studies 
and DNTs in rats, there is no evidence that pyrethroids directly impact 
developing fetuses. Additionally, none of the studies show any 
indications of fetal/offspring toxicity at doses that do not cause 
maternal toxicity. However, since there remains some uncertainty as to 
juvenile sensitivity due to the findings in the high-dose 
LD50 studies, EPA is retaining a FQPA SF for infants and 
children less than 6 years of age. This age group is a close 
approximation to the most sensitive human population, children from 
birth to <6 years old. EPA is seeking additional data to further 
characterize the potential neurotoxic risk pyrethroid toxicity. 
However, EPA has reliable data that show that reducing the FQPA SF to 
3X will protect the safety of infants and children. These data include:
    (a) data from guideline studies with zeta-cypermethrin at 
relatively high doses that show no sensitivity with regard to 
neurotoxic effects (the most sensitive effect for the pyrethroids) and 
no residual concern regarding overall

[[Page 7273]]

juvenile sensitivity (i.e., sensitivity seen in body weight changes 
occurred at doses above the level chosen for the POD);
    (b) data showing that the potential sensitivity at high doses is 
due to pharmacokinetics alone;
    (c) a rat PBPK model predicting a three-fold increase of pyrethroid 
concentration in juvenile brain compared to adults at high doses due to 
age-dependent pharmacokinetics; and
    (d) data indicating that the rat is a conservative model compared 
to the human based on species-specific pharmacodynamics of homologous 
sodium channel isoforms.
    For several reasons, EPA concludes these data show that a 3X factor 
is protective of the safety of infants and children. First, it is 
likely that the extensive guideline studies with zeta-cypermethrin 
showing no neurotoxicity sensitivity between adults and juveniles 
better characterize the potential sensitivity of juvenile animals than 
the LD50 studies. The high doses that produced juvenile 
sensitivity in the literature studies are well above normal dietary or 
residential exposure levels of pyrethroids to juveniles and lower 
levels of exposure anticipated from dietary and residential uses are 
not expected to overwhelm the juvenile's ability to metabolize 
pyrethroids, as occurred with the high doses used in the literature 
studies. The lack of increased neurotoxic sensitivity of the young in 
the overwhelming majority (69 of 70) of the prenatal and postnatal 
guideline studies for pyrethroids supports this conclusion, despite the 
relatively high doses used in those studies. Second, limited in vitro 
and in vivo data indicate similar pharmacodynamic response to 
pyrethroids between juvenile and adult rats. The portion of the 
uncertainty factor that accounts for potential pharmacodynamic 
differences between animals and humans (i.e., the inter-species 
extrapolation factor) is likely to overstate the risk of the 
cypermethrins given the data showing similarities in pharmacodynamics 
between animals and humans. For the inter-species factor, the 
pharmacodynamic portion of the factor is generally considered to be 3X. 
However, for pyrethroids the actual difference is likely to be lower 
than 3X. In addition, there are data that show that there are no 
lifestage pharmacodynamic differences between young and adult rats. 
Standard uncertainty factors, such as those used in the cypermethrin 
risk assessment, assume that there will be such differences. Finally, 
as indicated, pharmacokinetic modeling only predicts a 3X difference 
between juveniles and adults. Thus, even if there is increased juvenile 
neurotoxic sensitivity and even if the existing interspecies and 
intraspecies factors do not provide extra protection due to the 
conservative nature of their pharmacodynamic components for 
pyrethroids, the 3X additional factor will protect the young. 
Therefore, the FQPA factor of 3X is protective of potential juvenile 
sensitivity.

E. Aggregate Risks and Determination of Safety

    EPA determines whether acute and chronic dietary pesticide 
exposures are safe by comparing aggregate exposure estimates to the 
aPAD and cPAD. For linear cancer risks, EPA calculates the lifetime 
probability of acquiring cancer given the estimated aggregate exposure. 
Short-, intermediate-, and chronic-term risks are evaluated by 
comparing the estimated aggregate food, water, and residential exposure 
to the appropriate PODs to ensure that an adequate MOE exists.
    1. Acute risk. Using the exposure assumptions discussed in this 
unit for acute exposure, the acute dietary exposure from food and water 
to alpha-cypermethrin will occupy 87% of the aPAD for all infants (<1 
year old) and children 1-2 years old, the population groups receiving 
the greatest exposure. This assessment is considered to be 
conservative, because tolerance level residues and distributions of 
field trial data (as opposed to monitoring data) were used for many 
commodities. Additionally, although upper-bound estimates were used for 
drinking water, drinking water is not considered to be a major source 
of dietary exposure for the cypermethrins.
    2. Chronic risk. Separate chronic and cancer dietary risk 
assessments were not conducted for the cypermethrins. Because of the 
rapid reversibility of the most sensitive neurotoxicity endpoint used 
for quantifying risks, there is no increase in hazard with increasing 
dosing duration, and therefore the acute dietary endpoint is protective 
for chronic and cancer dietary exposures.
    3. Short-term risk. Short-term aggregate exposure takes into 
account short-term residential exposure plus chronic exposure to food 
and water (considered to be a background exposure level).
    Cypermethrin and zeta-cypermethrin are currently registered for 
uses that could result in short-term residential exposure, and the 
Agency has determined that it is appropriate to aggregate chronic 
exposure through food and water with short-term residential exposures 
to the cypermethrins including alpha-cypermethrin.
    For assessing short-term aggregate risk, the average dietary 
exposure estimate was used since it represents a background exposure 
level from food and drinking water that may co-occur with residential 
exposures. Dietary and oral (hand to mouth) risks for children, and 
dietary and inhalation risks for adults were combined in this 
assessment, since the toxicological endpoints were the same. However, 
the level of concern (LOC) values were different (oral adults and 
children >=6 years old = 100; children <6 years old = 300), while 
inhalation LOC = 30. Therefore, the respective risk estimates are 
combined using the aggregate risk index (ARI) approach. When this 
approach is used, aggregate risks are not of concern provided the 
calculated ARI is greater than 1. The ARI for adults was calculated to 
be 56 and the ARI for children was 2.3. Because these ARIs are greater 
than 1, the risk estimates are not of concern.
    4. Intermediate-term risk. Intermediate-term aggregate exposure 
takes into account intermediate-term residential exposure plus chronic 
exposure to food and water (considered to be a background exposure 
level). An intermediate-term aggregate risk assessment was not 
conducted because the cypermethrins are acutely toxic and do not 
increase in potency with repeated dosing. Because the neurotoxicity POD 
used for acute risk assessment is lower (more protective) than PODs for 
longer durations of exposure and acute and short-term exposure levels 
are higher than longer term exposure levels, the acute and short-term 
aggregate assessments are protective for intermediate-term aggregate 
risks anticipated from the cypermethrins.
    5. Aggregate cancer risk for U.S. population. For the reasons 
discussed in Unit III.A. (cancer effects are non-linear and appear at 
higher doses than acute effects) and Unit III.E.2. (chronic exposures 
are lower than acute exposures), the acute aggregate assessment is 
protective of potential cancer risk.
    6. Determination of safety. Based on these risk assessments, EPA 
concludes that there is a reasonable certainty that no harm will result 
to the general population, or to infants and children from aggregate 
exposure to the cypermethrin residues.

[[Page 7274]]

IV. Other Considerations

A. Analytical Enforcement Methodology

    Adequate tolerance-enforcement methods are available in PAM Volume 
II for determining residues of cypermethrin, zeta-cypermethrin and 
alpha-cypermethrin in plant (Method I) and livestock (Method II) 
commodities. Both methods are gas chromatographic methods with 
electron-capture detection (GC/ECD), and have undergone successful 
Agency petition method validations (PMVs). Method I has a limit of 
detection (LOD) of 0.01 ppm, and Method II has LODs of 0.005 ppm in 
milk, and 0.01 ppm in livestock tissues. These methods are not 
stereospecific; thus no distinction is made between residues of 
cypermethrin (all eight stereoisomers), zeta-cypermethrin (enriched in 
four isomers) and alpha-cypermethrin (two isomers).

B. International Residue Limits

    In making its tolerance decisions, EPA seeks to harmonize U.S. 
tolerances with international standards whenever possible, consistent 
with U.S. food safety standards and agricultural practices. EPA 
considers the international maximum residue limits (MRLs) established 
by the Codex Alimentarius Commission (Codex), as required by FFDCA 
section 408(b)(4). The Codex Alimentarius is a joint United Nations 
Food and Agriculture Organization/World Health Organization food 
standards program, and it is recognized as an international food safety 
standards-setting organization in trade agreements to which the United 
States is a party. EPA may establish a tolerance that is different from 
a Codex MRL; however, FFDCA section 408(b)(4) requires that EPA explain 
the reasons for departing from the Codex level.
    There are multiple Codex MRLs for alpha-cypermethrin, but all are 
in conjunction with MRLs for total cypermethrin isomers (no MRLs have 
been established solely for alpha-cypermethrin). However, although the 
definitions of the isomers covered differ formally between U.S. 
tolerances and Codex MRLs, the definitions of coverage are effectively 
harmonized since the tolerance enforcement methods are not 
stereospecific, and thus do not distinguish between residues of 
cypermethrin, zeta-cypermethrin and alpha-cypermethrin. For enforcement 
purposes, the same moiety is being regulated. As to harmonization of 
tolerance levels, U.S. tolerances and Codex MRLs are identical for tree 
nuts, tomatoes, and cattle meat byproducts. However, the proposed U.S. 
use patterns for all of the other crops for which U.S. tolerances are 
being established differ from the use patterns underlying the Codex 
MRLs associated with these crops. Therefore, these U.S. tolerances 
cannot be established at the same level as the Codex MRLs.

C. Response to Comments

    There were no comments received on this petition.

D. Revisions to Petitioned-For Tolerances

    No revisions to the tolerance levels in the petition, as proposed 
by BASF, were necessary. However, all the proposed commodity 
definitions (except for soybean, seed) were revised to reflect the 
correct commodity definitions, per the Agency's current commodity 
vocabulary. Additionally, appropriate tolerances for alpha-cypermethrin 
in livestock commodities (which were not proposed by BASF) were added 
(reflecting those established for zeta-cypermethrin), based on the 
potential for residues in livestock feed items associated with the 
proposed uses.

V. Conclusion

    Therefore, tolerances are established for residues of alpha-
cypermethrin ((R)-cyano(3-phenoxyphenyl)methyl (1S,3S)-rel-3-(2,2-
dichloroethenyl)-2,2-dimethylcyclopropane carboxylate, in or on cotton, 
undelinted seed, vegetable, legume, edible podded, subgroup 6A, and 
sorghum, grain, grain at 0.50 ppm; vegetable, root and tuber, group 1, 
except sugar beet, pea and bean, succulent shelled, subgroup 6B, and 
hog, fat at 0.10 ppm; nut, tree, group 14-12, pea and bean, dried 
shelled, except soybean, subgroup 6C, corn, field, grain, corn, pop, 
grain, corn, sweet, kernel plus cob with husks removed, soybean, seed, 
beet, sugar, roots, cattle, meat byproducts, egg, goat, meat 
byproducts, hog, meat, horse, meat byproducts, poultry, fat, poultry, 
meat, and sheep, meat byproducts at 0.05 ppm; vegetable, leafy, group 4 
at 10 ppm; Brassica, head and stem, subgroup 5A at 2.0 ppm; rice, grain 
at 1.5 ppm; vegetable, cucurbit, group 9, vegetable, fruiting, group 8-
10, beet, sugar, tops, wheat, grain, cattle, meat, goat, meat, horse, 
meat, and sheep, meat at 0.20 ppm; fruit, citrus, group 10-10 at 0.35 
ppm; citrus, oil at 4.0 ppm; citrus, dried pulp at 1.8 ppm; alfalfa, 
hay at 15 ppm; cattle, fat, goat, fat, horse, fat, sheep, fat at 1.0 
ppm; and milk, fat, reflecting at 0.10 ppm in whole milk at 2.5 ppm.

VI. Statutory and Executive Order Reviews

    This final rule establishes tolerances under FFDCA section 408(d) 
in response to a petition submitted to the Agency. The Office of 
Management and Budget (OMB) has exempted these types of actions from 
review under Executive Order 12866, entitled ``Regulatory Planning and 
Review'' (58 FR 51735, October 4, 1993). Because this final rule has 
been exempted from review under Executive Order 12866, this final rule 
is not subject to Executive Order 13211, entitled ``Actions Concerning 
Regulations That Significantly Affect Energy Supply, Distribution, or 
Use'' (66 FR 28355, May 22, 2001) or Executive Order 13045, entitled 
``Protection of Children from Environmental Health Risks and Safety 
Risks'' (62 FR 19885, April 23, 1997). This final rule does not contain 
any information collections subject to OMB approval under the Paperwork 
Reduction Act (PRA) (44 U.S.C. 3501 et seq.), nor does it require any 
special considerations under Executive Order 12898, entitled ``Federal 
Actions to Address Environmental Justice in Minority Populations and 
Low-Income Populations'' (59 FR 7629, February 16, 1994).
    Since tolerances and exemptions that are established on the basis 
of a petition under FFDCA section 408(d), such as the tolerance in this 
final rule, do not require the issuance of a proposed rule, the 
requirements of the Regulatory Flexibility Act (RFA) (5 U.S.C. 601 et 
seq.), do not apply.
    This final rule directly regulates growers, food processors, food 
handlers, and food retailers, not States or tribes, nor does this 
action alter the relationships or distribution of power and 
responsibilities established by Congress in the preemption provisions 
of FFDCA section 408(n)(4). As such, the Agency has determined that 
this action will not have a substantial direct effect on States or 
tribal governments, on the relationship between the national government 
and the States or tribal governments, or on the distribution of power 
and responsibilities among the various levels of government or between 
the Federal Government and Indian tribes. Thus, the Agency has 
determined that Executive Order 13132, entitled ``Federalism'' (64 FR 
43255, August 10, 1999) and Executive Order 13175, entitled 
``Consultation and Coordination with Indian Tribal Governments'' (65 FR 
67249, November 9, 2000) do not apply to this final rule. In addition, 
this final rule does not impose any enforceable duty or contain any 
unfunded mandate

[[Page 7275]]

as described under Title II of the Unfunded Mandates Reform Act of 1995 
(UMRA) (2 U.S.C. 1501 et seq.).
    This action does not involve any technical standards that would 
require Agency consideration of voluntary consensus standards pursuant 
to section 12(d) of the National Technology Transfer and Advancement 
Act of 1995 (NTTAA) (15 U.S.C. 272 note).

VII. Congressional Review Act

    Pursuant to the Congressional Review Act (5 U.S.C. 801 et seq.), 
EPA will submit a report containing this rule and other required 
information to the U.S. Senate, the U.S. House of Representatives, and 
the Comptroller General of the United States prior to publication of 
the rule in the Federal Register. This action is not a ``major rule'' 
as defined by 5 U.S.C. 804(2).

List of Subjects in 40 CFR Part 180

    Environmental protection, Administrative practice and procedure, 
Agricultural commodities, Pesticides and pests, Reporting and 
recordkeeping requirements.

    Dated: January 23, 2013.
Steven Bradbury,
Director, Office of Pesticide Programs.

    Therefore, 40 CFR chapter I is amended as follows:

PART 180--[AMENDED]

0
1. The authority citation for part 180 continues to read as follows:

    Authority:  21 U.S.C. 321(q), 346a and 371.


0
2. In Sec.  180.418 add paragraph (a)(3) to read as follows:


Sec.  180.418  Cypermethrin and an isomer alpha-cypermethrin; 
tolerances for residues.

    (a) * * *
    (3) Tolerances are established for residues of the insecticide, 
alpha-cypermethrin, (R)-cyano(3-phenoxyphenyl)methyl (1S,3S)-rel-3-
(2,2-dichloroethenyl)-2,2-dimethylcyclopropane carboxylate, including 
its metabolites and degradates, in or on the commodities in the table 
below. Compliance with the tolerance levels specified below is to be 
determined by measuring only total cypermethrin, cyano(3-
phenoxyphenyl)methyl 3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropane 
carboxylate, in or on the commodity.

------------------------------------------------------------------------
                                                               Parts per
                          Commodity                             million
------------------------------------------------------------------------
Alfalfa, hay................................................       15
Beet, sugar, roots..........................................        0.05
Beet, sugar, tops...........................................        0.20
Brassica, head and stem, subgroup 5A........................        2.0
Cattle, fat.................................................        1.0
Cattle, meat................................................        0.20
Cattle, meat byproducts.....................................        0.05
Citrus, dried pulp..........................................        1.8
Citrus, oil.................................................        4.0
Corn, field, grain..........................................        0.05
Corn, pop, grain............................................        0.05
Corn, sweet, kernel plus cob with husks removed.............        0.05
Cotton, undelinted seed.....................................        0.50
Egg.........................................................        0.05
Fruit, citrus, group 10-10..................................       10
Goat, fat...................................................        1.0
Goat, meat..................................................        0.20
Goat, meat byproducts.......................................        0.05
Hog, fat....................................................        1.0
Hog, meat...................................................        0.05
Horse, fat..................................................        1.0
Horse, meat.................................................        0.20
Horse, meat byproducts......................................        0.05
Milk, fat, reflecting 0.10 ppm in whole milk................        2.5
Nut, tree, group 14-12......................................        0.05
Pea and bean, dried shelled, except soybean, subgroup 6C....        0.05
Pea and bean, succulent shelled, subgroup 6B................        0.10
Poultry, fat................................................        0.05
Poultry, meat...............................................        0.05
Rice, grain.................................................        1.5
Sheep, fat..................................................        1.0
Sheep, meat.................................................        0.20
Sheep, meat byproducts......................................        0.05
Sorghum, grain, grain.......................................        0.50
Soybean, seed...............................................        0.05
Vegetable, cucurbit, group 9................................        0.20
Vegetable, fruiting, group 8-10.............................        0.20
Vegetable, leafy, group 4...................................       10
Vegetable, legume, edible podded, subgroup 6A...............        0.50
Vegetable, root and tuber, group 1, except sugar beet.......        0.10
Wheat, grain................................................        0.20
------------------------------------------------------------------------

* * * * *
[FR Doc. 2013-02206 Filed 1-31-13; 8:45 am]
BILLING CODE 6560-50-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.